John V Heymach

List of Publications by Year
in descending order

733	52,827	1798 103	1899 208
papers	citations	h-index	g-index

768	768	768	54264
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comprehensive molecular profiling of lung adenocarcinoma. Nature, 2014, 511, 543-550.	13.7	4,572
2	Comprehensive genomic characterization of squamous cell lung cancers. Nature, 2012, 489, 519-525.	13.7	3,483
3	Lung Cancer. New England Journal of Medicine, 2008, 359, 1367-1380.	13.9	2,271
4	STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. Cancer Discovery, 2018, 8, 822-835.	7.7	1,108
5	Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Nonâ€“Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. Journal of Clinical Oncology, 2019, 37, 1558-1565.	0.8	882
6	Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncology, The, 2016, 17, 1672-1682.	5.1	865
7	An Epithelialâ€“Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. Clinical Cancer Research, 2013, 19, 279-290.	3.2	848
8	Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 2014, 346, 256-259.	6.0	834
9	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications, 2014, 5, 5241.	5.8	780
10	The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery, 2011, 1, 44-53.	7.7	778
11	Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. Cancer Discovery, 2015, 5, 860-877.	7.7	696
12	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer, 2019, 19, 289-297.	12.8	692
13	PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models withEGFRandERBB2Mutations that Are Resistant to Gefitinib. Cancer Research, 2007, 67, 11924-11932.	0.4	674
14	Co-occurring genomic alterations inÂnon-small-cell lung cancer biology and therapy. Nature Reviews Cancer, 2019, 19, 495-509.	12.8	573
15	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 2019, 9, 646-661.	7.7	555
16	Tepotinib in Nonâ€“Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. New England Journal of Medicine, 2020, 383, 931-943.	13.9	500
17	A pan-cancer proteomic perspective on The Cancer Genome Atlas. Nature Communications, 2014, 5, 3887.	5.8	456
18	STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Research, 2016, 76, 999-1008.	0.4	451

#	Article	IF	Citations
19	Phase II Trial of Infusional Fluorouracil, Irinotecan, and Bevacizumab for Metastatic Colorectal Cancer: Efficacy and Circulating Angiogenic Biomarkers Associated With Therapeutic Resistance. Journal of Clinical Oncology, 2010, 28, 453-459.	0.8	440
20	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. Cancer Discovery, 2012, 2, 798-811.	7.7	432
21	Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome. Journal of the National Cancer Institute, 2012, 104, 228-239.	3.0	424
22	Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Journal of Clinical Investigation, 2006, 116, 2695-2706.	3.9	423
23	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell, 2021, 39, 346-360.e7.	7.7	422
24	Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncology, The, 2010, 11, 619-626.	5.1	407
25	Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy. Cell Metabolism, 2018, 27, 977-987.e4.	7.2	398
26	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2016, 22, 609-620.	3.2	388
27	Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2013, 31, 895-902.	0.8	366
28	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nature Medicine, 2021, 27, 504-514.	15.2	357
29	Epithelialâ€“Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. Clinical Cancer Research, 2016, 22, 3630-3642.	3.2	353
30	Mechanisms and clinical activity of an EGFR and HER2 exon 20â€“selective kinase inhibitor in nonâ€“small cell lung cancer. Nature Medicine, 2018, 24, 638-646.	15.2	351
31	Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses. Clinical Cancer Research, 2016, 22, 1103-1110.	3.2	326
32	An integrinÂÎ²3â€“KRASâ€“RalB complex drives tumour stemness and resistance to EGFR inhibition. Nature Cell Biology, 2014, 16, 457-468.	4.6	325
33	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. Cancer Discovery, 2018, 8, 1156-1175.	7.7	323
34	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discovery, 2017, 7, 620-629.	7.7	321
35	Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2017, 35, 1341-1367.	0.8	318
36	Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance. Clinical Cancer Research, 2009, 15, 3484-3494.	3.2	297

#	Article	IF	Citations
37	Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clinical Cancer Research, 2018, 24, 6195-6203.	3.2	292
38	Randomized, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel in Previously Treated Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2007, 25, 4270-4277.	0.8	286
39	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respiratory Medicine,the, 2021, 9, 467-475.	5.2	277
40	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	0.8	276
41	Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?. Cancer Immunology Research, 2014, 2, 831-838.	1.6	270
42	Beyond VEGF: Inhibition of the Fibroblast Growth Factor Pathway and Antiangiogenesis. Clinical Cancer Research, 2011, 17, 6130-6139.	3.2	262
43	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. Clinical Cancer Research, 2017, 23, 1388-1396.	3.2	261
44	Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma. Journal of Clinical Oncology, 2007, 25, 4952-4960.	0.8	258
45	Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 1813-1822.	0.8	243
46	Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncology, The, 2012, 13, 827-837.	5.1	240
47	MuSE: accounting for tumor heterogeneity using a sample-specific error model improves sensitivity and specificity in mutation calling from sequencing data. Genome Biology, 2016, 17, 178.	3.8	231
48	Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases. Cancer Discovery, 2019, 9, 628-645.	7.7	231
49	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. Nature, 2017, 546, 168-172.	13.7	222
50	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	5.7	218
51	Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2008, 26, 5407-5415.	0.8	214
52	Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro-Oncology, 2012, 14, 1379-1392.	0.6	205
53	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Journal of Thoracic Oncology, 2020, 15, 709-740.	0.5	205
54	Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2007, 13, 2643-2650.	3.2	202

#	Article	IF	Citations
55	Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancer. Nature Cancer, 2020, 1, 176-183.	5.7	201
56	LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Research, 2019, 79, 3251-3267.	0.4	196
57	14-3-3Î¶ Cooperates with ErbB2 to Promote Ductal Carcinoma In Situ Progression to Invasive Breast Cancer by Inducing Epithelial-Mesenchymal Transition. Cancer Cell, 2009, 16, 195-207.	7.7	195
58	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. Cancer Cell, 2017, 31, 225-239.	7.7	190
59	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. Lung Cancer, 2017, 112, 90-95.	0.9	188
60	Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature, 2021, 597, 732-737.	13.7	185
61	Phase II Study of Recombinant Human Endostatin in Patients With Advanced Neuroendocrine Tumors. Journal of Clinical Oncology, 2006, 24, 3555-3561.	0.8	180
62	Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors. Journal of Clinical Oncology, 2017, 35, 352-360.	0.8	175
63	Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer. Molecular Therapy, 2014, 22, 1494-1503.	3.7	172
64	Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer. Clinical Cancer Research, 2013, 19, 6322-6328.	3.2	171
65	miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1/VEGFR1. Molecular Cancer Research, 2011, 9, 25-35.	1.5	166
66	KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling. Journal of Clinical Investigation, 2013, 123, 5231-5246.	3.9	164
67	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. Cancer Research, 2017, 77, 3870-3884.	0.4	163
68	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discovery, 2017, 7, 1088-1097.	7.7	160
69	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget, 2017, 8, 28575-28587.	0.8	157
70	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. Journal of Thoracic Oncology, 2016, 11, 453-474.	0.5	156
71	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncology, The, 2021, 22, 1448-1457.	5.1	154
72	Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses. Clinical Cancer Research, 2009, 15, 267-273.	3.2	153

#	Article	IF	Citations
73	Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status. Journal of Thoracic Oncology, 2022, 17, 399-410.	0.5	151
74	Robust Gene Expression Signature from Formalin-Fixed Paraffin-Embedded Samples Predicts Prognosis of Nonâ€“Small-Cell Lung Cancer Patients. Clinical Cancer Research, 2011, 17, 5705-5714.	3.2	150
75	Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC. Journal of Thoracic Oncology, 2021, 16, 205-215.	0.5	149
76	Differential Effects of Vascular Endothelial Growth Factor Receptor-2 Inhibitor ZD6474 on Circulating Endothelial Progenitors and Mature Circulating Endothelial Cells: Implications for Use as a Surrogate Marker of Antiangiogenic Activity. Clinical Cancer Research, 2005, 11, 3514-3522.	3.2	145
77	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity. Cancer Cell, 2019, 36, 444-457.e7.	7.7	145
78	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. , 2020, 8, e001001.		143
79	Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitorâ€“resistant human lung adenocarcinoma. Journal of Clinical Investigation, 2011, 121, 1313-1328.	3.9	141
80	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 3638-3647.	0.8	140
81	Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications, 2020, 11, 603.	5.8	140
82	Metronomic Chemotherapy Enhances the Efficacy of Antivascular Therapy in Ovarian Cancer. Cancer Research, 2007, 67, 281-288.	0.4	138
83	CXCR2 Expression in Tumor Cells Is a Poor Prognostic Factor and Promotes Invasion and Metastasis in Lung Adenocarcinoma. Cancer Research, 2013, 73, 571-582.	0.4	138
84	Relationship Between Tumor Size and Survival in Nonâ€“Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry. Journal of Thoracic Oncology, 2015, 10, 682-690.	0.5	133
85	Genomic heterogeneity of multiple synchronous lung cancer. Nature Communications, 2016, 7, 13200.	5.8	132
86	Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion on Investigational Drugs, 2007, 16, 239-249.	1.9	131
87	Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2010, 28, 193-201.	0.8	131
88	Two conserved domains in the NGF propeptide are necessary and sufficient for the biosynthesis of correctly processed and biologically active NGF.. EMBO Journal, 1991, 10, 2395-2400.	3.5	130
89	Image Analysisâ€“based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Nonâ€“small Cell Lung Carcinoma Patients. Clinical Cancer Research, 2016, 22, 6278-6289.	3.2	130
90	HIF2Î± cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 2160-2170.	3.9	129

#	Article	IF	Citations
91	Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a Target in LKB1-Mutant Lung Cancer. Cancer Discovery, 2013, 3, 870-879.	7.7	127
92	Molecular targets for cancer chemoprevention. Nature Reviews Drug Discovery, 2009, 8, 213-225.	21.5	126
93	Effect of neoadjuvant chemotherapy on the immune microenvironment in nonâ€“small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
94	A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Annals of Oncology, 2012, 23, 46-52.	0.6	125
95	7â€year followâ€up after stereotactic ablative radiotherapy for patients with stage I nonâ€“small cell lung cancer: Results of a phase 2 clinical trial. Cancer, 2017, 123, 3031-3039.	2.0	125
96	Cytokine profile and prognostic significance of high neutrophil-lymphocyte ratio in colorectal cancer. British Journal of Cancer, 2015, 112, 1088-1097.	2.9	123
97	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	5.8	122
98	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Nonâ€“Small Cell Lung Cancer. JAMA Oncology, 2017, 3, e172032.	3.4	119
99	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Molecular Cell, 2019, 76, 838-851.e5.	4.5	119
100	Neurotrophins induce release of neurotrophins by the regulated secretory pathway. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 9614-9619.	3.3	118
101	Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Nonâ€“Small Cell Lung Cancer Patients Treated with Pazopanib. Cancer Research, 2010, 70, 2171-2179.	0.4	116
102	Therapeutic Efficacy of Endostatin Exhibits a Biphasic Dose-Response Curve. Cancer Research, 2005, 65, 11044-11050.	0.4	114
103	Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget, 2016, 7, 3548-3558.	0.8	114
104	Erlotinib and the Risk of Oral Cancer. JAMA Oncology, 2016, 2, 209.	3.4	111
105	The SUMO E3-ligase PIAS1 Regulates the Tumor Suppressor PML and Its Oncogenic Counterpart PML-RARA. Cancer Research, 2012, 72, 2275-2284.	0.4	109
106	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	0.5	109
107	Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. Journal of Clinical Oncology, 2018, 36, 1020-1044.	0.8	108
108	Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. , 2021, 9, e002891.		107

#	Article	IF	Citations
109	The Association of Alternate VEGF Ligands with Resistance to Anti-VEGF Therapy in Metastatic Colorectal Cancer. PLoS ONE, 2013, 8, e77117.	1.1	106
110	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 6852-6861.	3.2	105
111	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. Journal of Thoracic Oncology, 2019, 14, 1912-1923.	0.5	105
112	Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Nonâ€“Small-Cell Lung Cancer after Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2013, 8, 222-228.	0.5	104
113	Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell, 2018, 173, 864-878.e29.	13.5	102
114	A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components. Science Translational Medicine, 2020, 12, .	5.8	101
115	Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.. Journal of Clinical Oncology, 2019, 37, 8504-8504.	0.8	101
116	Phase II Study of the Antiangiogenic Agent SU5416 in Patients with Advanced Soft Tissue Sarcomas. Clinical Cancer Research, 2004, 10, 5732-5740.	3.2	100
117	Deep learning-based prediction of the T cell receptorâ€“antigen binding specificity. Nature Machine Intelligence, 2021, 3, 864-875.	8.3	99
118	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. Journal of Thoracic Oncology, 2020, 15, 248-257.	0.5	97
119	Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?. Journal of Clinical Oncology, 2012, 30, 441-444.	0.8	96
120	Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with Î²-blockers. Science Translational Medicine, 2017, 9, .	5.8	96
121	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. Journal of Thoracic Oncology, 2020, 15, 777-791.	0.5	94
122	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 6239-6253.	3.2	93
123	Prognostic Impact of Radiation Therapy to the Primary Tumor in Patients With Non-small Cell Lung Cancer and Oligometastasis at Diagnosis. International Journal of Radiation Oncology Biology Physics, 2012, 84, e61-e67.	0.4	92
124	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. Cancer Research, 2017, 77, 6119-6130.	0.4	92
125	Phase 1â€“2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncology, The, 2011, 12, 1109-1117.	5.1	91
126	Targeted Therapies for Lung Cancer. Cancer Journal (Sudbury, Mass), 2011, 17, 512-527.	1.0	91

#	Article	IF	Citations
127	Integrative Analysis Identifies a Novel AXLâ€“PI3 Kinaseâ€“PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. Clinical Cancer Research, 2017, 23, 2713-2722.	3.2	91
128	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. Nature Communications, 2019, 10, 2978.	5.8	91
129	Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2009, 15, 3600-3609.	3.2	90
130	Functional Characterization of CLPTM1L as a Lung Cancer Risk Candidate Gene in the 5p15.33 Locus. PLoS ONE, 2012, 7, e36116.	1.1	89
131	The Regulated Secretion and Vectorial Targeting of Neurotrophins in Neuroendocrine and Epithelial Cells. Journal of Biological Chemistry, 1996, 271, 25430-25437.	1.6	88
132	Selective Antitumor Activity of Ibrutinib in EGFR-Mutant Nonâ€“Small Cell Lung Cancer Cells. Journal of the National Cancer Institute, 2014, 106, .	3.0	88
133	Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy. , 2019, 7, 237.		88
134	Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1Î± in non-small cell lung cancer cells. Oncogene, 2010, 29, 2616-2627.	2.6	87
135	A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Annals of Oncology, 2018, 29, 1561-1568.	0.6	87
136	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiationâ€“Related Abscopal Responses. Cancer Immunology Research, 2019, 7, 1903-1909.	1.6	86
137	Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Research, 2003, 63, 8345-50.	0.4	85
138	Long-term actions of vector-derived nerve growth factor or brain-derived neurotrophic factor on choline acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience, 1999, 90, 815-821.	1.1	83
139	Strategies for combining immunotherapy with radiation for anticancer therapy. Immunotherapy, 2015, 7, 967-980.	1.0	83
140	Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. Annals of Oncology, 2004, 15, 1187-1193.	0.6	82
141	Epidermal Growth Factor Receptor Inhibitors in Development for the Treatment of Nonâ€“Small Cell Lung Cancer: Table 1.. Clinical Cancer Research, 2006, 12, 4441s-4445s.	3.2	82
142	Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors. Cell Reports, 2017, 19, 1669-1684.	2.9	82
143	DNA Repair Biomarker Profiling of Head and Neck Cancer: Ku80 Expression Predicts Locoregional Failure and Death following Radiotherapy. Clinical Cancer Research, 2011, 17, 2035-2043.	3.2	81
144	Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Letters, 2015, 357, 179-185.	3.2	81

#	Article	IF	Citations
145	The Prognostic and Therapeutic Role of Genomic Subtyping by Sequencing Tumor or Cell-Free DNA in Pulmonary Large-Cell Neuroendocrine Carcinoma. Clinical Cancer Research, 2020, 26, 892-901.	3.2	80
146	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. Journal of Thoracic Oncology, 2019, 14, 2152-2163.	0.5	80
147	Global analysis of shared TÂcell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity, 2021, 54, 586-602.e8.	6.6	80
148	A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer. Journal of the National Cancer Institute, 2019, 111, 372-379.	3.0	79
149	PD-L1 Expression, Tumor Mutational Burden, and Cancer Gene Mutations Are Stronger Predictors of Benefit from Immune Checkpoint Blockade than HLA Class I Genotype in Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, 1021-1031.	0.5	79
150	LCE: an open web portal to explore gene expression and clinical associations in lung cancer. Oncogene, 2019, 38, 2551-2564.	2.6	78
151	Vandetanib Restores Head and Neck Squamous Cell Carcinoma Cells' Sensitivity to Cisplatin and Radiation In Vivo and In Vitro. Clinical Cancer Research, 2011, 17, 1815-1827.	3.2	76
152	OA02.06 A Phase II Trial of Poziotinib in EGFR and HER2 exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2018, 13, S323-S324.	0.5	76
153	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nature Communications, 2021, 12, 2722.	5.8	74
154	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. Oncotarget, 2017, 8, 73419-73432.	0.8	74
155	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Molecular Cancer Research, 2017, 15, 45-58.	1.5	73
156	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. Molecular Cancer Therapeutics, 2014, 13, 2738-2750.	1.9	72
157	ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1-mutant lung cancer. Nature Cancer, 2021, 2, 503-514.	5.7	72
158	Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, 102-102.	0.8	72
159	Poziotinib in Nonâ€“Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. Journal of Clinical Oncology, 2022, 40, 710-718.	0.8	72
160	Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma. Annals of Oncology, 2015, 26, 1476-1480.	0.6	71
161	Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clinical Lung Cancer, 2020, 21, 341-348.	1.1	70
162	Multiple receptor tyrosine kinases regulate HIF-1Î± and HIF-2Î± in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene, 2010, 29, 2938-2949.	2.6	69

#	Article	IF	Citations
163	Dual Targeting of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor Pathways: Rationale and Clinical Applications for Non-Small-Cell Lung Cancer. Clinical Lung Cancer, 2007, 8, S79-S85.	1.1	68
164	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. Cancer Discovery, 2021, 11, 2506-2523.	7.7	68
165	Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer. Clinical Cancer Research, 2016, 22, 5851-5863.	3.2	67
166	ZD6474 â€“ clinical experience to date. British Journal of Cancer, 2005, 92, S14-S20.	2.9	66
167	A phase 2 pilot trial of lowâ€dose, continuous infusion, or â€œmetronomicâ€•paclitaxel and oral celecoxib in patients with metastatic melanoma. Cancer, 2010, 116, 1751-1756.	2.0	65
168	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. PLoS ONE, 2016, 11, e0152584.	1.1	65
169	The Biosynthesis of Neurotrophin Heterodimers by Transfected Mammalian Cells. Journal of Biological Chemistry, 1995, 270, 12297-12304.	1.6	64
170	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. Clinical Cancer Research, 2016, 22, 4643-4650.	3.2	64
171	Vascular endothelial growth factor accelerates compensatory lung growth after unilateral pneumonectomy. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L742-L747.	1.3	63
172	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. Molecular Therapy - Nucleic Acids, 2015, 4, e270.	2.3	63
173	VEGF/VEGFR-2 Upregulates EZH2 Expression in Lung Adenocarcinoma Cells and EZH2 Depletion Enhances the Response to Platinum-Based and VEGFR-2â€“Targeted Therapy. Clinical Cancer Research, 2014, 20, 3849-3861.	3.2	62
174	Relation between the level of lymph node metastasis and survival in locally advanced head and neck squamous cell carcinoma. Cancer, 2016, 122, 534-545.	2.0	62
175	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. Journal of Thoracic Oncology, 2021, 16, 583-600.	0.5	62
176	Propensity Scoreâ€“Matched Analysis of Comprehensive Local Therapy for Oligometastatic Non-Small Cell Lung Cancer That Did Not Progress After Front-Line Chemotherapy. International Journal of Radiation Oncology Biology Physics, 2014, 90, 850-857.	0.4	61
177	Proteogenomic Analysis of Salivary Adenoid Cystic Carcinomas Defines Molecular Subtypes and Identifies Therapeutic Targets. Clinical Cancer Research, 2023, 27, 852-864.	3.2	61
178	Subcellular localization of epitope-tagged neurotrophins in neuroendocrine cells. , 1998, 51, 463-472.		59
179	Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle, 2008, 7, 3747-3758.	1.3	59
180	Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. Clinical Cancer Research, 2011, 17, 4872-4881.	3.2	59

#	Article	IF	Citations
181	Second-Line Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2008, 3, 430-440.	0.5	58
182	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. Lung Cancer, 2015, 89, 76-79.	0.9	58
183	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology, 2020, 15, 266-273.	0.5	58
184	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. Journal of Thoracic Oncology, 2010, 5, 1894-1904.	0.5	57
185	Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial. Clinical Cancer Research, 2013, 19, 6967-6975.	3.2	57
186	The Influence of Body Mass Index on Overall SurvivalÂFollowing Surgical Resection of Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1280-1287.	0.5	57
187	Multiregion gene expression profiling reveals heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer. Modern Pathology, 2018, 31, 947-955.	2.9	56
188	Inhibition of Thioredoxin/Thioredoxin Reductase Induces Synthetic Lethality in Lung Cancers with Compromised Glutathione Homeostasis. Cancer Research, 2019, 79, 125-132.	0.4	56
189	Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Nonâ€“Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy. Cancer Research, 2011, 71, 5512-5521.	0.4	55
190	The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2017, 23, 5489-5501.	3.2	55
191	Steroid Receptor Coactivator-3 Expression in Lung Cancer and Its Role in the Regulation of Cancer Cell Survival and Proliferation. Cancer Research, 2010, 70, 6477-6485.	0.4	54
192	Control of HIF-1Î± Expression by eIF2Î± Phosphorylationâ€“Mediated Translational Repression. Cancer Research, 2009, 69, 1836-1843.	0.4	53
193	Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion. Molecular Cancer Therapeutics, 2012, 11, 2021-2032.	1.9	53
194	PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions. Cancer Prevention Research, 2017, 10, 684-693.	0.7	53
195	Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Nonâ€“Small Cell Lung Carcinoma Tumors. Journal of Thoracic Oncology, 2018, 13, 779-791.	0.5	53
196	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. Journal of Thoracic Oncology, 2020, 15, 1919-1927.	0.5	53
197	Poziotinib for Patients With HER2 Exon 20 Mutant Nonâ€“Small-Cell Lung Cancer: Results From a Phase II Trial. Journal of Clinical Oncology, 2022, 40, 702-709.	0.8	53
198	Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice. Clinical Cancer Research, 2022, 28, 1117-1126.	3.2	52

#	Article	IF	Citations
199	Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells. Microvascular Research, 2008, 76, 15-22.	1.1	51
200	Long-Term Outcomes of Salvage Stereotactic AblativeÂRadiotherapy for Isolated Lung Recurrence of Nonâ€“Small Cell Lung Cancer: A Phase II Clinical Trial. Journal of Thoracic Oncology, 2017, 12, 983-992.	0.5	51
201	Artesunate suppresses the viability and mobility of prostate cancer cells through UCA1, the sponge of miR-184. Oncotarget, 2017, 8, 18260-18270.	0.8	51
202	Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors. British Journal of Cancer, 2011, 105, 382-392.	2.9	50
203	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clinical Cancer Research, 2017, 23, 5648-5656.	3.2	50
204	Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma. Journal of Thoracic Oncology, 2022, 17, 779-792.	0.5	50
205	Effect of Low-Fat Diets on Plasma Levels of NF-ÎºBâ€“Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer. Cancer Prevention Research, 2011, 4, 1590-1598.	0.7	48
206	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. Clinical Cancer Research, 2015, 21, 3480-3491.	3.2	48
207	Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Network Open, 2018, 1, e181390.	2.8	48
208	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Antiâ€“PD1-Resistant Lung Tumor Model. Clinical Cancer Research, 2018, 24, 5735-5743.	3.2	48
209	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. Journal of Thoracic Oncology, 2021, 16, 127-139.	0.5	48
210	Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium. Molecular Cancer Therapeutics, 2008, 7, 418-424.	1.9	47
211	Modulation of câ€Met signaling and cellular sensitivity to radiation. Cancer, 2013, 119, 1768-1775.	2.0	47
212	Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumabâ€¯+â€¯Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. Clinical Lung Cancer, 2022, 23, e247-e251.	1.1	47
213	Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors Vandetanib (ZD6474) and AZD2171 in Lung Cancer. Clinical Cancer Research, 2007, 13, 4617s-4622s.	3.2	45
214	C-Met Inhibitor MK-8003 Radiosensitizes c-Metâ€“Expressing Nonâ€“Small-Cell Lung Cancer Cells With Radiation-Induced c-Metâ€“Expression. Journal of Thoracic Oncology, 2012, 7, 1211-1217.	0.5	45
215	Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelialâ€“mesenchymal transition. BMC Genomics, 2014, 15, 1079.	1.2	45
216	Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models. Oncogene, 2018, 37, 3686-3697.	2.6	45

#	Article	IF	Citations
217	Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Nonâ€“small-cell Lung Cancer (NSCLC). Clinical Lung Cancer, 2019, 20, 43-47.	1.1	45
218	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open, 2020, 5, e000799.	2.0	45
219	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiotherapy and Oncology, 2021, 162, 60-67.	0.3	45
220	Realizing the Potential of Plasma Genotyping in an Age of Genotype-Directed Therapies. Journal of the National Cancer Institute, 2014, 106, dju214-dju214.	3.0	44
221	PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition. Cancer Biology and Therapy, 2015, 16, 402-411.	1.5	44
222	Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer. Scientific Reports, 2014, 4, 4480.	1.6	44
223	Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, 37-46.e7.	1.1	44
224	Farnesyl Transferase Inhibitors for Patients with Lung Cancer. Clinical Cancer Research, 2004, 10, 4254s-4257s.	3.2	44
225	STK11/LKB1 Mutations in NSCLC Are Associated with KEAP1/NRF2-Dependent Radiotherapy Resistance Targetable by Glutaminase Inhibition. Clinical Cancer Research, 2021, 27, 1720-1733.	3.2	44
226	The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention. Clinical Cancer Research, 2007, 13, 4035-4041.	3.2	43
227	The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies. Journal of Thoracic Oncology, 2008, 3, S131-S134.	0.5	43
228	Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer. Molecular Cancer Therapeutics, 2010, 9, 1755-1763.	1.9	43
229	Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. Journal of Thoracic Oncology, 2020, 15, 1611-1623.	0.5	43
230	Endothelial progenitor cells contribute to accelerated liver regeneration. Journal of Pediatric Surgery, 2007, 42, 1190-1198.	0.8	42
231	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nature Communications, 2021, 12, 5045.	5.8	42
232	Vascular Endothelial Growth Factor (VEGF) Pathway. Journal of Thoracic Oncology, 2006, 1, 768-770.	0.5	41
233	Tumor Endothelial Markers Define Novel Subsets of Cancer-Specific Circulating Endothelial Cells Associated with Antitumor Efficacy. Cancer Research, 2014, 74, 2731-2741.	0.4	41
234	Epithelialâ€“Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitorâ€“Mediated Apoptosis in Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2016, 22, 1674-1686.	3.2	41

#	Article	IF	Citations
235	Next-Generation CDK2/9 Inhibitors and Anaphase Catastrophe in Lung Cancer. Journal of the National Cancer Institute, 2017, 109, .	3.0	41
236	Radiological tumour classification across imaging modality and histology. Nature Machine Intelligence, 2021, 3, 787-798.	8.3	41
237	Vascular Endothelial Growth Factor (VEGF) Pathway. Journal of Thoracic Oncology, 2006, 1, 768-770.	0.5	40
238	Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours. British Journal of Cancer, 2015, 112, 1199-1205.	2.9	40
239	Prevalence of recurrent oncogenic fusion in mismatch repair-deficient colorectal carcinoma with hypermethylated MLH1 and wild-type BRAF and KRAS. Modern Pathology, 2019, 32, 1053-1064.	2.9	40
240	Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1. Journal of Molecular Medicine, 2019, 97, 49-61.	1.7	40
241	Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199297.	1.4	40
242	Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 601-609.	0.5	40
243	Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer, 2016, 17, e5-e11.	1.1	39
244	miR-125a-5p Functions as Tumor Suppressor microRNA And Is a Marker of Locoregional Recurrence And Poor prognosis in Head And Neck Cancer. Neoplasia, 2019, 21, 849-862.	2.3	39
245	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
246	DNA methylation intratumor heterogeneity in localized lung adenocarcinomas. Oncotarget, 2017, 8, 21994-22002.	0.8	39
247	An IRAK1â€“PIN1 signalling axis drives intrinsic tumour resistance to radiation therapy. Nature Cell Biology, 2019, 21, 203-213.	4.6	38
248	Applying Artificial Intelligence to Address the Knowledge Gaps in Cancer Care. Oncologist, 2019, 24, 772-782.	1.9	38
249	Angiogenesis and antiangiogenic approaches to sarcomas. Current Opinion in Oncology, 2001, 13, 261-269.	1.1	37
250	Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo. Clinical Cancer Research, 2008, 14, 2785-2795.	3.2	37
251	Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 900-907.	0.4	37
252	CDKN2A/p16 Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Research, 2018, 78, 781-797.	0.4	37

#	Article	IF	Citations
253	Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations. Clinical Lung Cancer, 2019, 20, 30-36.e3.	1.1	37
254	Monitoring seasonal influenza epidemics by using internet search data with an ensemble penalized regression model. Scientific Reports, 2017, 7, 46469.	1.6	36
255	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â‰¥50%) nonâ€“small cell lung cancer and a poor performance status. , 2020, 8, e001007.		36
256	Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biology, 2020, 21, 271.	3.8	36
257	A High Content Clonogenic Survival Drug Screen Identifies MEK Inhibitors as Potent Radiation Sensitizers for KRAS Mutant Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 965-973.	0.5	35
258	191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC. Journal of Thoracic Oncology, 2016, 11, S139-S140.	0.5	35
259	MicroRNA-related genetic variants in iron regulatory genes, dietary iron intake, microRNAs and lung cancer risk. Annals of Oncology, 2017, 28, 1124-1129.	0.6	35
260	Î²-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers. Journal of NeuroImmune Pharmacology, 2020, 15, 27-36.	2.1	35
261	Association of EGFR and HER-2 exon 20 mutations with distinct patterns of response to immune checkpoint blockade in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 9052-9052.	0.8	35
262	Enhanced PI3K p110Î± Signaling Confers Acquired Lapatinib Resistance That Can Be Effectively Reversed by a p110Î±-Selective PI3K Inhibitor. Molecular Cancer Therapeutics, 2014, 13, 60-70.	1.9	34
263	Predictive biomarkers in precision medicine and drug development against lung cancer. Chinese Journal of Cancer, 2015, 34, 295-309.	4.9	34
264	Altered Regulation of HIF-1Î± in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype. Journal of Thoracic Oncology, 2021, 16, 439-451.	0.5	34
265	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2â€“Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. Journal of Thoracic Oncology, 2021, 16, 1821-1839.	0.5	34
266	Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell, 2022, 40, 754-767.e6.	7.7	34
267	Synergistic antiâ€proliferative and proâ€apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with antiâ€epidermal growth factor receptor (EGFR) drugs in human cancer cells. Journal of Cellular Physiology, 2008, 216, 698-707.	2.0	33
268	Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters. PLoS ONE, 2012, 7, e31087.	1.1	33
269	De novo lipogenesis represents a therapeutic target in mutant Kras nonâ€small cell lung cancer. FASEB Journal, 2018, 32, 7018-7027.	0.2	33
270	Advanced Nonâ€“Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e187-e197.	1.8	33

#	Article	IF	Citations
271	Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. , 2020, 8, e000405.		33
272	MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. Current Opinion in Oncology, 2016, 28, 195-200.	1.1	32
273	Axl Receptor Axis: A New Therapeutic Target in LungÂCancer. Journal of Thoracic Oncology, 2016, 11, 1357-1362.	0.5	32
274	AXL Inhibition Induces DNA Damage and Replication Stress in Nonâ€“Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. Molecular Cancer Research, 2021, 19, 485-497.	1.5	32
275	HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells. Head and Neck, 2014, 36, 1547-1554.	0.9	31
276	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy for Resected Nonâ€“small Cell Lung Cancer. Clinical Cancer Research, 2018, 24, 341-350.	3.2	31
277	Profiles of brain metastases: Prioritization of therapeutic targets. International Journal of Cancer, 2018, 143, 3019-3026.	2.3	31
278	Tumor characteristics associated with engraftment of patientâ€derived nonâ€“small cell lung cancer xenografts in immunocompromised mice. Cancer, 2019, 125, 3738-3748.	2.0	31
279	Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. Oncotarget, 2016, 7, 565-579.	0.8	31
280	Inhibition of Intra-Abdominal Adhesion Formation With the Angiogenesis Inhibitor Sunitinib. Journal of Surgical Research, 2008, 149, 115-119.	0.8	30
281	Antitumor activity of a novel STAT3 inhibitor and redox modulator in non-small cell lung cancer cells. Biochemical Pharmacology, 2012, 83, 1456-1464.	2.0	30
282	Identification of predictors of drug sensitivity using patient-derived models of esophageal squamous cell carcinoma. Nature Communications, 2019, 10, 5076.	5.8	30
283	Multifactorial Deep Learning Reveals Pan-Cancer Genomic Tumor Clusters with Distinct Immunogenomic Landscape and Response to Immunotherapy. Clinical Cancer Research, 2020, 26, 2908-2920.	3.2	30
284	Pulmonary resection is associated with long-term survival and should remain a therapeutic option in oligometastatic lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1497-1504.e2.	0.4	30
285	Evolution of DNA methylome from precancerous lesions to invasive lung adenocarcinomas. Nature Communications, 2021, 12, 687.	5.8	30
286	Abstract 1719: Superior efficacy of neoadjuvant compared to adjuvant immune checkpoint blockade in non-small cell lung cancer. Cancer Research, 2018, 78, 1719-1719.	0.4	30
287	Angiogenesis inhibitors and hypoxia. Nature Medicine, 2003, 9, 1104-1104.	15.2	29
288	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer, 2018, 120, 137-141.	0.9	29

#	Article	IF	Citations
289	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. British Journal of Cancer, 2019, 120, 340-345.	2.9	29
290	Distinct co-acquired alterations and genomic evolution during TKI treatment in non-small-cell lung cancer patients with or without acquired T790M mutation. Oncogene, 2020, 39, 1846-1859.	2.6	29
291	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with nonâ€“small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1327-1337.	0.4	29
292	AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 TÂcells. Cell Reports Medicine, 2022, 3, 100554.	3.3	29
293	Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Chemonaive Patients With Unresectable Malignant Pleural Mesothelioma. Clinical Lung Cancer, 2014, 15, 197-201.	1.1	28
294	Circulating Biomarkers in Advanced Renal Cell Carcinoma: Clinical Applications. Current Oncology Reports, 2012, 14, 221-229.	1.8	27
295	Upregulation of lactate dehydrogenase a by 14-3-3Î¶ leads to increased glycolysis critical for breast cancer initiation and progression. Oncotarget, 2016, 7, 35270-35283.	0.8	27
296	Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 349-357.	0.4	27
297	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. Journal of Thoracic Oncology, 2021, 16, 1289-1297.	0.5	27
298	A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Journal of Clinical Oncology, 2005, 23, 3023-3023.	0.8	27
299	Pharmacodynamic analysis of target inhibition and endothelial cell death in tumors treated with the vascular endothelial growth factor receptor antagonists SU5416 or SU6668. Clinical Cancer Research, 2005, 11, 678-89.	3.2	27
300	Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 418-424.	0.7	26
301	Stereotactic ablative body radiation for oligometastatic and oligoprogressive disease. Translational Lung Cancer Research, 2018, 8, 97-106.	1.3	26
302	Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Nonâ€“Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clinical Lung Cancer, 2021, 22, e451-e465.	1.1	26
303	Bayesian randomized trial comparing intensity modulated radiation therapy versus passively scattered proton therapy for locally advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 8500-8500.	0.8	26
304	O-100 ZD6474 plus docetaxel in patients with previously treatedNSCLC: Results of a randomized, placebo-controlled Phase II trial. Lung Cancer, 2005, 49, S35-S36.	0.9	25
305	Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma. Cancer, 2009, 115, 2346-2354.	2.0	25
306	Sorafenib in non-small cell lung cancer. Expert Opinion on Investigational Drugs, 2012, 21, 1417-1426.	1.9	25

#	Article	IF	Citations
307	Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunology Research, 2017, 5, 319-329.	1.6	25
308	BAP1 Is a Novel Target in HPV-Negative Head and Neck Cancer. Clinical Cancer Research, 2018, 24, 600-607.	3.2	25
309	Targeting IL-1Î² as an immunopreventive and therapeutic modality for K-rasâ€“mutant lung cancer. JCI Insight, 2022, 7, .	2.3	25
310	A novel therapeutic combination for neuroblastoma. Cancer, 2010, 116, 2465-2475.	2.0	24
311	Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma. British Journal of Cancer, 2011, 105, 112-117.	2.9	24
312	The mutually regulatory loop of epithelialâ€“mesenchymal transition and immunosuppression in cancer progression. OncoImmunology, 2015, 4, e1002731.	2.1	24
313	Coexistent genetic alterations involving ALK, RET, ROS1 or MET in 15 cases of lung adenocarcinoma. Modern Pathology, 2018, 31, 307-312.	2.9	24
314	Local Consolidative Therapy (LCT) Improves Overall Survival (OS) Compared to Maintenance Therapy/Observation in Oligometastatic Non-Small Cell Lung Cancer (NSCLC): Final Results of a Multicenter, Randomized, Controlled Phase 2 Trial. International Journal of Radiation Oncology Biology Physics, 2018, 102, 1604.	0.4	24
315	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nature Communications, 2021, 12, 6655.	5.8	24
316	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. Journal of Thoracic Oncology, 2021, 16, 269-277.	0.5	23
317	Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. European Journal of Cardio-thoracic Surgery, 2021, 59, 100-108.	0.6	23
318	MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nature Communications, 2022, 13, 1797.	5.8	23
319	The Role of the Nerve Growth Factor Carboxyl Terminus in Receptor Binding and Conformational Stability. Journal of Biological Chemistry, 1997, 272, 29222-29228.	1.6	22
320	Phase II Trial of Carboplatin, Paclitaxel, Cetuximab, and Bevacizumab Followed by Cetuximab and Bevacizumab in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer: SWOG S0536. Journal of Thoracic Oncology, 2013, 8, 1519-1528.	0.5	22
321	Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage Iâ€“II Nonâ€“Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2014, 9, 675-684.	0.5	22
322	Joint prognostic effect of obesity and chronic systemic inflammation in patients with metastatic colorectal cancer. Cancer, 2015, 121, 2968-2975.	2.0	22
323	drexplorer: A tool to explore doseâ€“response relationships and drugâ€“drug interactions. Bioinformatics, 2015, 31, 1692-1694.	1.8	22
324	A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Nonâ€“Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 3525-3536.	3.2	22

#	Article	IF	Citations
325	EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).. Journal of Clinical Oncology, 2018, 36, TPS8581-TPS8581.	0.8	22
326	Vascular endothelial growth factor (VEGF) pathway. Journal of Thoracic Oncology, 2006, 1, 768-70.	0.5	22
327	Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis. Surgical Oncology, 2017, 26, 460-472.	0.8	21
328	An in vivo functional genomics screen of nuclear receptors and their co-regulators identifies FOXA1 as an essential gene in lung tumorigenesis. Neoplasia, 2020, 22, 294-310.	2.3	21
329	18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunology, Immunotherapy, 2020, 69, 1519-1534.	2.0	21
330	Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget, 2016, 7, 47998-48010.	0.8	21
331	Emerging Antiangiogenic Agents in Lung Cancer. Clinical Lung Cancer, 2006, 7, 304-308.	1.1	20
332	EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer. Annals of Oncology, 2014, 25, 1941-1948.	0.6	20
333	Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma. Head and Neck, 2016, 38, 439-447.	0.9	20
334	<scp>eIF</scp>2Î², a subunit of translationâ€initiation factor <scp>EIF</scp>2, is a potential therapeutic target for nonâ€small cell lung cancer. Cancer Science, 2018, 109, 1843-1852.	1.7	20
335	Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 742-750.	2.5	20
336	Clinical and Biomarker Outcomes of the Phase II Vandetanib Study from the BATTLE Trial. Journal of Thoracic Oncology, 2013, 8, 658-661.	0.5	19
337	Spatio-Temporal Genomic Heterogeneity, Phylogeny, and Metastatic Evolution in Salivary Adenoid Cystic Carcinoma. Journal of the National Cancer Institute, 2017, 109, .	3.0	19
338	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10⁺ advanced non-small cell lung cancer. , 2022, 10, e003581.		19
339	Different dietary patterns and reduction of lung cancer risk: A large case-control study in the U.S.. Scientific Reports, 2016, 6, 26760.	1.6	18
340	Identification of proteasomal catalytic subunit <scp>PSMA</scp>6 as a therapeutic target for lung cancer. Cancer Science, 2017, 108, 732-743.	1.7	18
341	Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies. International Journal of Radiation Oncology Biology Physics, 2017, 99, 1315.	0.4	18
342	Inhibition of nonsense-mediated decay rescues p53Î²/Î³ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers. Journal of Biological Chemistry, 2021, 297, 101163.	1.6	18

#	Article	IF	Citations
343	Taking it up a NOTCH: a novel subgroup of ACC is identified. Oncotarget, 2017, 8, 81725-81726.	0.8	18
344	Metabolic Responses to Metformin in Inoperable Early-stage Nonâ€“Small Cell Lung Cancer Treated With Stereotactic Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 231-235.	0.6	17
345	Targeting of CD40 and PD-L1 Pathways Inhibits Progression of Oral Premalignant Lesions in a Carcinogen-induced Model of Oral Squamous Cell Carcinoma. Cancer Prevention Research, 2021, 14, 313-324.	0.7	17
346	TGFÎ²1 Polymorphisms Predict Distant Metastasisâ€“Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. PLoS ONE, 2013, 8, e65659.	1.1	16
347	Endothelial progenitor cell mobilization by preoperative exercise: a bone marrow response associated with postoperative outcome. British Journal of Anaesthesia, 2014, 113, 652-660.	1.5	16
348	Analysis of Factors Affecting Successful Clinical Trial Enrollment in the Context of Three Prospective, Randomized, Controlled Trials. International Journal of Radiation Oncology Biology Physics, 2017, 97, 770-777.	0.4	16
349	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer, 2021, 154, 76-83.	0.9	16
350	Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population. Oncotarget, 2013, 4, 772-784.	0.8	16
351	The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nature Communications, 2021, 12, 7081.	5.8	16
352	KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clinical Cancer Research, 2016, 22, 1940-1950.	3.2	15
353	Quantitative Proteomic Analysis of Optimal Cutting Temperature (OCT) Embedded Core-Needle Biopsy of Lung Cancer. Journal of the American Society for Mass Spectrometry, 2017, 28, 2078-2089.	1.2	15
354	Circulating metabolite profiles to predict overall survival in advanced non-small cell lung cancer patients receiving first-line chemotherapy. Lung Cancer, 2017, 114, 70-78.	0.9	15
355	Genomic landscape of allelic imbalance in premalignant atypical adenomatous hyperplasias of the lung. EBioMedicine, 2019, 42, 296-303.	2.7	15
356	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clinical Cancer Research, 2020, 26, 5477-5486.	3.2	15
357	STK11/LKB1 co-mutations to predict for de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2017, 35, 9016-9016.	0.8	15
358	Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Nonâ€“Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab. JAMA Network Open, 2022, 5, e2215589.	2.8	15
359	Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy. Journal of Thoracic Oncology, 2008, 3, S107-S112.	0.5	14
360	TRACERx: Tracking tumor evolution to impact the course of lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1199-1202.	0.4	14

#	Article	IF	Citations
361	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. Journal of Thoracic Oncology, 2018, 13, 246-257.	0.5	14
362	Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Seminars in Oncology, 2019, 46, 145-154.	0.8	14
363	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clinical Cancer Research, 2019, 25, 346-357.	3.2	14
364	Urothelial cancer harbours EGFR and HER2 amplifications and exon 20 insertions. BJU International, 2020, 125, 739-746.	1.3	14
365	Risk Factors for and Time to Recurrence of Symptomatic Malignant Pleural Effusion in Patients With Metastatic Non-Small Cell Lung Cancer with EGFR or ALK Mutations. Chest, 2021, 159, 1256-1264.	0.4	14
366	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma. Cancer Immunology, Immunotherapy, 2021, 70, 1965-1976.	2.0	14
367	A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).. Journal of Clinical Oncology, 2016, 34, 8512-8512.	0.8	14
368	Circulating Biomarkers of Response to Sunitinib in Gastroenteropancreatic Neuroendocrine Tumors. Molecular Diagnosis and Therapy, 2012, 16, 151-161.	1.6	13
369	8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS ONE, 2015, 10, e0135962.	1.1	13
370	Plasma Riboflavin Level is Associated with Risk, Relapse, and Survival of Esophageal Squamous Cell Carcinoma. Nutrition and Cancer, 2017, 69, 21-28.	0.9	13
371	Blood-based tumor mutation burden: continued progress toward personalizing immunotherapy in non-small cell lung cancer. Journal of Thoracic Disease, 2019, 11, 2208-2211.	0.6	13
372	Validation of the 12-gene Predictive Signature for Adjuvant Chemotherapy Response in Lung Cancer. Clinical Cancer Research, 2019, 25, 150-157.	3.2	13
373	Interim safety and pharmacodynamic results for ALN-VSP02, a novel RNAi therapeutic for solid tumors with liver involvement.. Journal of Clinical Oncology, 2010, 28, 3042-3042.	0.8	13
374	Circulating protein and cellular biomarkers of sunitinib in patients with advanced neuroendocrine tumors.. Journal of Clinical Oncology, 2011, 29, 4079-4079.	0.8	13
375	ENGAGE-1: A first in human study of the OX40 agonist GSK3174998 alone and in combination with pembrolizumab in patients with advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, TPS3107-TPS3107.	0.8	13
376	MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial. Journal of Thoracic Oncology, 2017, 12, S406-S407.	0.5	12
377	Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinoma. British Journal of Cancer, 2017, 117, 478-484.	2.9	12
378	Influence of Surveillance PET/CT on Detection of Early Recurrence After Definitive Radiation in Stage III Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2017, 18, 141-148.	1.1	12

#	Article	IF	Citations
379	Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer. Journal of Translational Medicine, 2018, 16, 328.	1.8	12
380	Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer. Lung Cancer, 2020, 149, 33-40.	0.9	12
381	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. Npj Precision Oncology, 2021, 5, 21.	2.3	12
382	Levels of circulating endothelial cells (CECs) and monocytes as pharmacodynamic markers of SU11248 activity in patients (pts) with metastatic imatinib-resistant GIST. Journal of Clinical Oncology, 2005, 23, 9036-9036.	0.8	12
383	Updated incidence rates and risk factors of esophageal cancer in Nan'ao Island, a coastal high-risk area in southern China. Ecological Management and Restoration, 2016, 30, n/a-n/a.	0.2	11
384	Erlotinib plus either pazopanib or placebo in patients with previously treated advanced nonâ€“small cell lung cancer: A randomized, placeboâ€controlled phase 2 trial with correlated serum proteomic signatures. Cancer, 2018, 124, 2355-2364.	2.0	11
385	Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cellâ€free DNA by nextâ€generation sequencing. Cancer, 2018, 124, 1061-1069.	2.0	11
386	Patterns of protein expression in human head and neck cancer cell lines differ after proton vs photon radiotherapy. Head and Neck, 2020, 42, 289-301.	0.9	11
387	Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report. Clinical Lung Cancer, 2020, 21, 384-388.	1.1	11
388	Clinical Outcomes in Nonâ€“Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precision Oncology, 2021, 5, 1241-1249.	1.5	11
389	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes. , 2022, 10, e003082.		11
390	Neuronal self-reliance. Nature, 1995, 374, 405-406.	13.7	10
391	Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Targeted Oncology, 2013, 8, 117-125.	1.7	10
392	Single nucleotide polymorphism rs13042395 in the SLC52A3 gene as a biomarker for regional lymph node metastasis and relapse-free survival of esophageal squamous cell carcinoma patients. BMC Cancer, 2016, 16, 560.	1.1	10
393	Hypoxia pathway genetic variants predict survival of non-small-cell lung cancer patients receiving platinum-based chemotherapy. Carcinogenesis, 2017, 38, 419-424.	1.3	10
394	Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations. BMC Cancer, 2020, 20, 83.	1.1	10
395	Female Gender Predicts Augmented Immune Infiltration in Lung Adenocarcinoma. Clinical Lung Cancer, 2021, 22, e415-e424.	1.1	10
396	Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.. Journal of Clinical Oncology, 2016, 34, 9069-9069.	0.8	10

#	Article	IF	Citations
397	SABR vs surgery for NSCLC in the media. Lancet Oncology, The, 2015, 16, e422.	5.1	9
398	Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. ESMO Open, 2017, 2, e000102.	2.0	9
399	Powerful statistical method to detect diseaseâ€associated genes using publicly available genomeâ€wide association studies summary data. Genetic Epidemiology, 2019, 43, 941-951.	0.6	9
400	Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Annals of Thoracic Surgery, 2020, 109, 358-366.	0.7	9
401	New Verse for a Familiar Song: Small Molecule Inhibitors for MET exon 14 Skipping Non-Small Cell Lung Cancer. Oncologist, 2020, 25, 822-825.	1.9	9
402	A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers. Molecular Cancer Therapeutics, 2021, 20, 477-489.	1.9	9
403	Abstract A11: Lower baseline levels of plasma hepatocyte growth factor, IL-6, and IL-8 are correlated with greater tumor shrinkage in renal cell carcinoma patients treated with pazopanib. Molecular Cancer Therapeutics, 2009, 8, A11-A11.	1.9	9
404	Outcome analysis of Phase I trial patients with metastaticKRASand/orTP53mutant non-small cell lung cancer. Oncotarget, 2018, 9, 33258-33270.	0.8	9
405	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clinical Cancer Research, 2022, 28, 2461-2473.	3.2	9
406	Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Nonâ€“Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precision Oncology, 2021, 5, 1802-1812.	1.5	9
407	Developmental neurobiology Neurotrophins moving forward. Nature, 1997, 389, 789-791.	13.7	8
408	OA 12.01 The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC. Journal of Thoracic Oncology, 2017, 12, S1776.	0.5	8
409	What Do Patients With Nonâ€“Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncology Practice, 2020, 16, e1151-e1160.	1.4	8
410	LKB1/STK11 Expression in Lung Adenocarcinoma and Associations With Patterns of Recurrence. Annals of Thoracic Surgery, 2020, 110, 1131-1138.	0.7	8
411	ZD6474, a novel antiangiogenic agent, in combination with docetaxel in patients with NSCLC: Results of the run-in phase of a two-part, randomized phase II study. Journal of Clinical Oncology, 2004, 22, 3051-3051.	0.8	8
412	A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. Journal of Clinical Oncology, 2008, 26, 5093-5093.	0.8	8
413	DETERRED: PD-L1 blockade to evaluate the safety of lung cancer therapy using carboplatin, paclitaxel, and radiation combined with MPDL3280A (atezolizumab).. Journal of Clinical Oncology, 2017, 35, 3064-3064.	0.8	8
414	Genomic and transcriptomic landscape of oral pre-cancers (OPCs) and risk of oral cancer (OC).. Journal of Clinical Oncology, 2019, 37, 6009-6009.	0.8	8

#	Article	IF	Citations
415	I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.. Journal of Clinical Oncology, 2020, 38, 9035-9035.	0.8	8
416	Efficacy of Targeted Inhibitors in Metastatic Lung Squamous Cell Carcinoma With EGFR or ALK Alterations. JTO Clinical and Research Reports, 2021, 2, 100237.	0.6	8
417	Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook. Molecular Diagnosis and Therapy, 2012, 16, 151-61.	1.6	8
418	Angiogenesis Inhibitors for Lung Cancer: Clinical Developments and Future Directions. Journal of Thoracic Oncology, 2006, 1, 744-748.	0.5	7
419	MA04.07 Impact of Major Co-Mutations on the Immune Contexture and Response of KRAS-Mutant Lung Adenocarcinoma to Immunotherapy. Journal of Thoracic Oncology, 2017, 12, S361-S362.	0.5	7
420	P1.07-024 EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact. Journal of Thoracic Oncology, 2017, 12, S710-S711.	0.5	7
421	A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist, 2020, 25, e1457-e1463.	1.9	7
422	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. Cancers, 2021, 13, 1250.	1.7	7
423	A phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with hepatocellular carcinoma. Journal of Clinical Oncology, 2005, 23, 4120-4120.	0.8	7
424	EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.. Journal of Clinical Oncology, 2017, 35, TPS8575-TPS8575.	0.8	7
425	Initial safety assessment of MAGE-A10c796TCR T-cells in two clinical trials.. Journal of Clinical Oncology, 2018, 36, 3056-3056.	0.8	7
426	SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.. Journal of Clinical Oncology, 2018, 36, 8514-8514.	0.8	7
427	M10-01: Molecular pathogenesis of lung cancer with translation to the clinic. Journal of Thoracic Oncology, 2007, 2, S178-S179.	0.5	6
428	Quantitative Evaluation of Drug-induced Microvascular Constriction in Mice Kidney Using a Novel Tool for 3D Geometrical Analysis of Ex vivo Organ Vasculature. Toxicologic Pathology, 2014, 42, 774-783.	0.9	6
429	Preliminary Results of a Phase II Study of Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC. Journal of Thoracic Oncology, 2017, 12, S1536.	0.5	6
430	Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. Journal of Thoracic Disease, 2020, 12, 1952-1959.	0.6	6
431	Estrogen Promotes Resistance to Bevacizumab in Murine Models of NSCLC. Journal of Thoracic Oncology, 2021, 16, 2051-2064.	0.5	6
432	ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer Cell, 2021, 39, 1178-1180.	7.7	6

#	Article	IF	Citations
433	Immune profiling of oral pre-malignant lesions (OPLs): An Erlotinib Prevention of Oral Cancer (EPOC) study biobank analysis.. Journal of Clinical Oncology, 2017, 35, 1545-1545.	0.8	6
434	An open-label, multidrug, biomarker-directed, multicentre phase II umbrella study in patients with non-small cell lung cancer, who progressed on an anti-PD-1/PD-L1 containing therapy (HUDSON).. Journal of Clinical Oncology, 2018, 36, TPS3120-TPS3120.	0.8	6
435	Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-Small Cell Lung Cancer with EGFR Mutations (NORTHSTAR). Annals of Surgical Oncology, 2022, 29, 4688-4689.	0.7	6
436	1404 POSTER DISCUSSION Baseline (BL) IL-6, IL-8, and VEGF as Predictive and Prognostic Markers for Overall Survival (OS) in Metastatic Renal Cell Carcinoma (mRCC) Patients (pts) Treated in a Phase III Trial of Pazopanib (PAZO) Versus Placebo (PL). European Journal of Cancer, 2011, 47, S170.	1.3	5
437	Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Annals of Thoracic Surgery, 2018, 105, 1621-1626.	0.7	5
438	Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2020, 107, 261-269.	0.4	5
439	Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.. Journal of Clinical Oncology, 2021, 39, 8528-8528.	0.8	5
440	Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors. Molecular Cancer Therapeutics, 2015, 14, C42-C42.	1.9	5
441	The KRAS-variant and treatment response in BATTLE-1.. Journal of Clinical Oncology, 2014, 32, 8135-8135.	0.8	5
442	Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.. Journal of Clinical Oncology, 2016, 34, 9073-9073.	0.8	5
443	Association of STK11/LKB1 mutations with primary resistance to PD-1/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC.. Journal of Clinical Oncology, 2018, 36, 9028-9028.	0.8	5
444	BRIGHTSTAR: A pilot trial of local consolidative therapy (LCT) with brigatinib in tyrosine kinase inhibitor (TKI)-naÃ¯ve ALK-rearranged advanced NSCLC.. Journal of Clinical Oncology, 2020, 38, 9624-9624.	0.8	5
445	KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. American Journal of Cancer Research, 2020, 10, 4464-4475.	1.4	5
446	Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treatment and Research Communications, 2022, 30, 100514.	0.7	5
447	Tumor-Infiltrating Lymphocytes and Overall Survival in Surgically Resected Stage II and III Nonâ€“Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 223.	0.4	4
448	Phase 1 Study of Pembrolizumab and Stereotactic or Hypofractionated Radiation for Metastatic Nonâ€“small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, S160-S161.	0.4	4
449	Randomized phase II trial of osimertinib with or without local consolidation therapy (LCT) for patients with EGFR-mutant metastatic NSCLC (NORTHSTAR). Annals of Oncology, 2018, 29, viii547.	0.6	4
450	HIF2Î± cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation, 2009, 119, 3182-3182.	3.9	4

#	Article	IF	Citations
451	Profiling of cytokines and angiogenic factors (C/AF) in head and neck (HN) cancer correlates circulating biomarkers with clinical outcomes following induction chemotherapy. Journal of Clinical Oncology, 2008, 26, 6005-6005.	0.8	4
452	BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2013, 31, TPS8118-TPS8118.	0.8	4
453	Local consolidative therapy (LCT) to improve progression-free survival (PFS) in patients with oligometastatic non-small cell lung cancer (NSCLC) who receive induction systemic therapy (IST): Results of a multi-institutional phase II randomized study.. Journal of Clinical Oncology, 2016, 34, 9004-9004.	0.8	4
454	Randomized, double-blind, placebo-controlled, phase II trial of first-line platinum/docetaxel with or without erlotinib (E) in patients (pts) with recurrent and/or metastatic (R/M) head and neck squamous cell carcinomas (HNSCCs).. Journal of Clinical Oncology, 2017, 35, 6017-6017.	0.8	4
455	Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR.. Journal of Clinical Oncology, 2018, 36, TPS8580-TPS8580.	0.8	4
456	Association of the T-cell receptor landscape with survival in non-small cell lung cancer.. Journal of Clinical Oncology, 2018, 36, 140-140.	0.8	4
457	Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Molecular Cancer Research, 2022, 20, 280-292.	1.5	4
458	ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer, 2022, 166, 112-125.	1.3	4
459	Latent feature decompositions for integrative analysis of diverse high-throughput genomic data. , 2012, , .		3
460	High Throughput Clonogenic Survival Screen Identifies Novel Radiation Sensitizers for K-ras Mutant Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S651.	0.4	3
461	2 Safety and early evidence of activity of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody OMP-52M51 (anti-Notch1) administered intravenously to patients with certain advanced solid tumors. European Journal of Cancer, 2014, 50, 7.	1.3	3
462	OA20.06 Prospective ImmunogenomiC PrOfiling of Non-Small Cell Lung Cancer - The ICON Project. Journal of Thoracic Oncology, 2017, 12, S324-S325.	0.5	3
463	MA 05.02 STK11/LKB1 Loss of Function Genomic Alterations Predict Primary Resistance to PD-1/PD-L1 Axis Blockade in KRAS-Mutant NSCLC. Journal of Thoracic Oncology, 2017, 12, S1815.	0.5	3
464	OA 13.05 Immune, Molecular and T Cell Repertoire Landscape of 235 Resected Non-Small Cell Lung Cancers and Paired Normal Lung Tissues. Journal of Thoracic Oncology, 2017, 12, S1780.	0.5	3
465	Germline and Somatic Smoothened Mutations in Nonâ€“Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precision Oncology, 2017, 1, 1-10.	1.5	3
466	Prognostic Factors as a Function of Disease-free Interval After Definitive (Chemo)radiation for Nonâ€“Small Cell Lung Cancer Using Conditional Survival Analysis. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 46-52.	0.6	3
467	MA19.10 Impact of STK11/LKB1 Genomic Alterations on Clinical Outcomes with Chemo-Immunotherapy in Non-Squamous NSCLC. Journal of Thoracic Oncology, 2018, 13, S424-S425.	0.5	3
468	P2.04-09 Driver Mutations are Associated with Distinct Patterns of Response to Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S733-S734.	0.5	3

#	Article	IF	Citations
469	A general statistic to test an optimally weighted combination of common and/or rare variants. Genetic Epidemiology, 2019, 43, 966-979.	0.6	3
470	Improved Overall Survival with Local Consolidative Therapy in Oligometastatic Non-Small Cell Lung Cancer: Results from a Cohort of 194 Patients with Synchronous Disease. International Journal of Radiation Oncology Biology Physics, 2019, 104, 229.	0.4	3
471	Abstract 2215: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer. , 2019, , .		3
472	Abstract 4885: AL101 mediated tumor inhibition in Notch mutated ACC PDX models. , 2019, , .		3
473	Baseline VEGF as a potential predictive biomarker of vandetanib clinical benefit in patients with advanced NSCLC. Journal of Clinical Oncology, 2008, 26, 8009-8009.	0.8	3
474	Association of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: Implications for immunotherapy biomarkers.. Journal of Clinical Oncology, 2014, 32, 3018-3018.	0.8	3
475	Notch1 mutations to define a subgroup of adenoid cystic carcinoma (ACC): Tumor stage, propensity to bone and liver metastasis, risk of relapse, and overall survival.. Journal of Clinical Oncology, 2015, 33, 6081-6081.	0.8	3
476	Histology determination of lung cancers: A report on genomic profiling of lung cancer of mixing histology.. Journal of Clinical Oncology, 2017, 35, 8570-8570.	0.8	3
477	Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.. Journal of Clinical Oncology, 2010, 28, 7516-7516.	0.8	3
478	Abstract 213: Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse. , 2018, , .		3
479	Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, S1-S11.	2.3	3
480	Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant nonâ€“small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2022, 40, 9105-9105.	0.8	3
481	Stage I lung cancerâ€”to operate or to radiate? that is the question. Journal of Thoracic Disease, 2016, 8, 2324-2327.	0.6	2
482	Selecting Reliable mRNA Expression Measurements across Platforms Improves Downstream Analysis. Cancer Informatics, 2016, 15, CIN.S38590.	0.9	2
483	MA 01.03 The Potential of ctDNA Sequencing in Disease Monitoring and Depicting Genomic Evolution of Small-Cell Lung Cancer Under Therapy. Journal of Thoracic Oncology, 2017, 12, S1800.	0.5	2
484	MA23.02 Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S438.	0.5	2
485	MA06.02 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON. Journal of Thoracic Oncology, 2018, 13, S375.	0.5	2
486	P1.03-13 eIF2Î², A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S516-S517.	0.5	2

#	Article	IF	Citations
487	Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Nonâ€“small-cell Lung Cancer. Clinical Lung Cancer, 2019, 20, e480-e488.	1.1	2
488	Polya tree priors and their estimation with multi-group data. Statistical Papers, 2019, 60, 849-875.	0.7	2
489	Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer, 2020, 146, 303-309.	0.9	2
490	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusionsâ€"A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. Journal of Clinical Oncology, 2021, 39, TPS449-TPS449.	0.8	2
491	Abstract 4256: High programmed cell death ligand 1 expression and low immune infiltrate score correlate with worse outcome in patients with lung adenocarcinoma. , 2015, , .		2
492	Abstract CT027: A phase I, open-label study of GSK3174998 administered alone and in combination with pembrolizumab in patients (pts) with selected advanced solid tumors (ENGAGE-1). , 2016, , .		2
493	Abstract 4686: T cell repertoire evolution from the normal lung to invasive lung adenocarcinoma. , 2018, , .		2
494	Abstract 4772: Poziotinib overcomes de novo resistance of HER2 exon 20 mutations in NSCLC and other cancers: Preclinical studies and initial clinical testing. , 2018, , .		2
495	Abstract 3772: Inter- and intra-tumoral variations in ASCL1, NEUROD1, and POU2F3 transcriptional programs underlie three distinct molecular subtypes of small cell lung cancers. , 2019, , .		2
496	Abstract B72: Combining immune checkpoint inhibition and DNA damage repair (DDR) targeted therapy in small cell lung cancer (SCLC). Cancer Immunology Research, 2017, 5, B72-B72.	1.6	2
497	Circulating endothelial cells are a potential biomarker for patients with renal cell carcinoma (RCC) with and without von Hippel Lindau (VHL) syndrome. Journal of Clinical Oncology, 2008, 26, 5098-5098.	0.8	2
498	Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study. Journal of Clinical Oncology, 2008, 26, 8010-8010.	0.8	2
499	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. Journal of Clinical Oncology, 2015, 33, 3608-3608.	0.8	2
500	A preclinical study of tumor-infiltrating lymphocytes in NSCLC.. Journal of Clinical Oncology, 2018, 36, 161-161.	0.8	2
501	Abstract 2875: p53 regulation of PDL1 is mediated through miR-34a. Cancer Research, 2015, 75, 2875-2875.	0.4	2
502	Two phase I/II open label clinical trials evaluating the safety and efficacy of autologous T cells expressing enhanced TCRs specific for NY-ESO-1 or MAGE-A10 in subjects with stage IIIb or stage IV non-small cell lung cancer (NCT02588612/NCT02592577).. Journal of Clinical Oncology, 2017, 35, TPS3096-TPS3096.	0.8	2
503	Abstract 2061: Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants. Cancer Research, 2017, 77, 2061-2061.	0.4	2
504	Angiogenesis Inhibitors for the Treatment of Lung Cancer. , 2008, , 409-426.		2

#	Article	IF	Citations
505	Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer, 2022, 164, 69-75.	0.9	2
506	Clinical Effectiveness And Safety Of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer. Clinical Lung Cancer, 2022, , .	1.1	2
507	Epstein Barr virusâ€“positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo. Blood Advances, 2022, 6, 891-901.	2.5	2
508	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2022, 41, 172.	3.5	2
509	Quantification of Circulating Endothelial Cells by Flow Cytometry. Clinical Cancer Research, 2009, 15, 3640-3640.	3.2	1
510	Mesothelioma and Small Cell Lung Cancer. Journal of Thoracic Oncology, 2011, 6, S1825-S1826.	0.5	1
511	Elevated Serum HGF Is Associated With Radioresistance and Local Recurrence in Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S652.	0.4	1
512	Phase 1 Study of Ipilimumab and Stereotactic Radiation Targeting Liver or Lung Lesions in Patients With Advanced Malignancies. International Journal of Radiation Oncology Biology Physics, 2015, 93, S208.	0.4	1
513	Can the Lung Cancer Pie Be Divided into Angiogenic Slices?. Clinical Cancer Research, 2015, 21, 5188-5190.	3.2	1
514	G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. European Journal of Cancer, 2016, 69, S143-S144.	1.3	1
515	MA14.03 The Impact of Genomic Landscape of EGFR Mutant NSCLC on Response to Targeted and Immune Therapy. Journal of Thoracic Oncology, 2017, 12, S423-S424.	0.5	1
516	P1.05-028 Phenotypic and Functional Profiling of Tumor-Infiltrating Lymphocytes (TIL) in Early Stage Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 2017, 12, S630-S631.	0.5	1
517	Intratumor Heterogeneity Is Associated with Survival of Patients with Stage IA Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, S1539.	0.5	1
518	TCR Repertoire of Lung Cancer: An Association with Tumor Molecular and Clinicopathological Features. Journal of Thoracic Oncology, 2017, 12, S1539.	0.5	1
519	Safety and anti-tumor effects of MAGE-A10c796 TCR T-cells in two clinical trials. Annals of Oncology, 2018, 29, viii731.	0.6	1
520	P3.01-109 Real-World Patient-Reported Outcome Assessment of Patients with Metastatic Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S907-S908.	0.5	1
521	Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC). Annals of Oncology, 2018, 29, viii680.	0.6	1
522	P1.13-37 Clinical Evaluation of Plasma-Based (cfDNA) Genomic Profiling in Over 1,000 Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S596-S597.	0.5	1

#	Article	IF	Citations
523	P3.01-91 Computing the Impact of Immunotherapy on the Non-Small Cell Lung Cancer (NSCLC) Therapeutic Landscape. Journal of Thoracic Oncology, 2018, 13, S901-S902.	0.5	1
524	Novel Cancer Immunotherapies and Antitumor Immunity. Journal of Immunology Research, 2019, 2019, 1-2.	0.9	1
525	Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib. JTO Clinical and Research Reports, 2020, 1, 100081.	0.6	1
526	Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.. , 2013, , .		1
527	Abstract C29: Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using an antibody independent method, ApoStreamâ„¢: An update report.. , 2013, , .		1
528	Abstract 376: Increased HGF is associated with resistance to VEGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC). Cancer Research, 2010, 70, 376-376.	0.4	1
529	Abstract LB-88: Gene expression signatures predictive of clinical outcome and tumor mutations in refractory NSCLC patients (pts) in the BATTLE trial (Biomarker-integrated Approaches of Targeted) Tj ETQq1 1 0.784314 rgBT /Overlo		
530	Abstract 4819: Gene-expression profiles predict sorafenib efficacy in wild-type EGFR non-small cell lung cancer (NSCLC). , 2012, , .		1
531	Abstract 142: Mutation and immune profiles in early-stage lung squamous cell carcinoma. Cancer Research, 2016, 76, 142-142.	0.4	1
532	Abstract 5734: The influence of body mass index on overall survival following surgical resection of non-small cell lung cancer. , 2017, , .		1
533	Abstract 4847: Evaluation of the combination of olaparib and cediranib in small-cell lung cancer cells. , 2018, , .		1
534	Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers. , 2019, , .		1
535	Association of activating NOTCH1 mutations in adenoid cystic carcinoma with shorter progression-free survival to systemic therapy.. Journal of Clinical Oncology, 2017, 35, 6089-6089.	0.8	1
536	Intratumor heterogeneity of stage IA lung adenocarcinoma by multiregion whole exome sequencing and association with survival.. Journal of Clinical Oncology, 2017, 35, 8545-8545.	0.8	1
537	Response to single-agent (SA) chemotherapy (CTx) after immunotherapy exposure in non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, 9083-9083.	0.8	1
538	Immunogenomic profiling of non-small cell lung cancer: The ICON project.. Journal of Clinical Oncology, 2017, 35, e20034-e20034.	0.8	1
539	Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism.. Journal of Clinical Oncology, 2018, 36, 2558-2558.	0.8	1
540	Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials.. Journal of Clinical Oncology, 2018, 36, 2590-2590.	0.8	1

#	Article	IF	Citations
541	Cediranib targeting of circulating VEGFR-1+ monocyte subpopulations. Journal of Clinical Oncology, 2008, 26, 14687-14687.	0.8	1
542	Relative impact of chemotherapy with or without bevacizumab on cytokines and angiogenic factors (CAFs) in metastatic colorectal cancer.. Journal of Clinical Oncology, 2011, 29, 401-401.	0.8	1
543	Abstract 3273: Estrogen contributes to bevacizumab resistance in xenograft models of non-small cell lung cancer (NSCLC). , 2011, , .		1
544	Plasma cytokines and angiogenic factors (CAFs) associated with risk of recurrence and tumor dependence in patients (pts) with nonmetastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2012, 30, 383-383.	0.8	1
545	Abstract IA21: Developing a new functional classification of lung cancer based on tumor acquired vulnerabilities.. Clinical Cancer Research, 2014, 20, IA21-IA21.	3.2	1
546	Abstract 5146: The histone demethylase KDM2A is a new promoter of tumorigenesis, drug target and negative prognostic biomarker for non-small cell lung cancer. , 2014, , .		1
547	Abstract 4710: Evaluation of the glutaminase inhibitor CB-839 in non-small cell lung cancer. , 2015, , .		1
548	Intra-tumor heterogeneity of T cell receptor repertoire in lung cancers and its association with tumor genomic profile.. Journal of Clinical Oncology, 2016, 34, 8539-8539.	0.8	1
549	Abstract A084: High OX-40 expression on the tumor immune infiltrate is a prognostic factor of better survival in non-small cell lung cancer. , 2016, , .		1
550	Abstract 5648: Combined immune checkpoint targeting with anti-PD-1 plus anti-CD40 antibodies as the most effective approach to eradicate head and neck squamous cell carcinomas (HNSCCs) in mouse models. , 2017, , .		1
551	FAK as a Target for Therapy in Head and Neck Cancer. Current Cancer Research, 2018, , 469-490.	0.2	1
552	Abstract 4054: Gene expression difference (GED) revealed immune function gene down-regulation as tumor-associated inflammatory cell (TAIC) infiltration in microenvironment in non-small cell lung cancer (NSCLC). , 2018, , .		1
553	Abstract 1174: Characterization of the immunologic intra-tumor heterogeneity in early stages of non-small cell lung carcinoma using multiplex immunofluorescence and image analysis approaches. , 2018, , .		1
554	Abstract 2408: LKB1 and KEAP1/NRF2 pathways cooperatively promote glutamine dependence and vulnerability to glutaminase inhibitors in KRAS-mutant lung adenocarcinoma. , 2018, , .		1
555	Abstract 5377: Tracking genomic and epigenomic evolution from preneoplastic lesions to lung adenocarcinoma by multiregion sequencing. , 2018, , .		1
556	Association of relative neutrophilia with a distinct immunoinhibitory milieu in non-small cell lung cancer.. Journal of Clinical Oncology, 2019, 37, e14047-e14047.	0.8	1
557	Abstract 2741: Comprehensive molecular profiling of primary tumors and paired distant metastases in non-small cell lung cancer. , 2019, , .		1
558	Abstract 2899: Single-cell analyses reveal increasing intratumoral heterogeneity as an essential component of treatment resistance in small cell lung cancer. , 2019, , .		1

#	Article	IF	Citations
559	Auto-reactive antibodies as predictive markers for immune checkpointâ€“induced pneumonitis.. Journal of Clinical Oncology, 2022, 40, 2554-2554.	0.8	1
560	Abstract CT212: A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations. Cancer Research, 2022, 82, CT212-CT212.	0.4	1
561	Clinical outcome and potential benefits of post-progression immunotherapy for patients with metastatic NSCLC with primary resistance to ipilumumab and nivolumab in the LONESTAR phase III study.. Journal of Clinical Oncology, 2022, 40, 9049-9049.	0.8	1
562	First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.. Journal of Clinical Oncology, 2022, 40, TPS2679-TPS2679.	0.8	1
563	A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations.. Journal of Clinical Oncology, 2022, 40, TPS9143-TPS9143.	0.8	1
564	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. Current Cancer Therapy Reviews, 2007, 3, 236-241.	0.2	0
565	C1-02: Randomized Phase II study of vandetanib alone or in combination with carboplatin and paclitaxel as 1st-line treatment for advanced NSCLC. Journal of Thoracic Oncology, 2007, 2, S358-S359.	0.5	0
566	Dr. Folkman's legacyâ€”a life of angiogenesis research. Apmis, 2008, 116, 89-92.	0.9	0
567	The Clinical Development of Vandetanib: Updates on Ongoing Phase III Clinical Trials in Advanced Nonâ€”Small-Cell Lung Cancer. Clinical Lung Cancer, 2008, 9, 292.	1.1	0
568	The Advantage of using PET SUV to Evaluate Tumor Response by RECIST Criteria in Patients with Stage IIIA/B Non-small Cell Lung Cancer (NSCLC) after Concurrent Chemotherapy and Tarceva with Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, S498.	0.4	0
569	Blasted Cell Line Names. Cancer Informatics, 2010, 9, CIN.S5613.	0.9	0
570	Predictive Factors Of Long-term Five Years Overall Survival Among Patients With Limited Small Cell Lung Cancer Treated With Radiation Treatment And Chemotherapy By Treatment Time Periods. International Journal of Radiation Oncology Biology Physics, 2011, 81, S588.	0.4	0
571	Limited-Stage Small Cell Lung Cancer in the Contemporary Period: Impact of New Technologies on Outcomes. International Journal of Radiation Oncology Biology Physics, 2012, 84, S592.	0.4	0
572	Poor Glycemic Control During Radiochemotherapy Contributes to Reduced Local Control and Overall Survival in Patients With Non-small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 84, S69-S70.	0.4	0
573	Implications of KRAS Mutations on Outcomes in Non-small Cell Lung Cancer Treated With Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 84, S70.	0.4	0
574	Patient Selection for Treatment Modality in Stage III Non-small Cell Lung Cancer: A Population-based Analysis. International Journal of Radiation Oncology Biology Physics, 2012, 84, S540-S541.	0.4	0
575	Treatment Modality and Other Prognostic Factors for Overall Survival in Stage III Non-small Cell Lung Cancer (NSCLC): A Population-based Analysis. International Journal of Radiation Oncology Biology Physics, 2012, 84, S540.	0.4	0
576	Duration of Thoracic Radiation Therapy With Concurrent Chemotherapy Is Important for the Outcome of Patients With Limited-Stage Small Cell Lung Cancer (L-SCLC). International Journal of Radiation Oncology Biology Physics, 2013, 87, S537.	0.4	0

#	Article	IF	Citations
577	Dosimetric Impact of Induction Chemotherapy on Subsequent Radiation Treatment Planning in Patients With Inoperable Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, S536-S537.	0.4	0
578	Improved 5-Year Disease Free-Survival and Distant Metastasis-Free Survival for Patients With Limited-Stage Small Cell Lung Cancer Who Had 18F-fluorodeoxyglucose Positron Emission Tomography (PET) or PET/CT Before Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 87, S536.	0.4	0
579	388 An integrated molecular analysis of lung adenocarcinomas identifies potential therapeutic targets among TTF1-negative tumors. European Journal of Cancer, 2014, 50, 124-125.	1.3	0
580	435 A pan-cancer tumor-derived epithelial-toâ€“mesenchymal transition (EMT) signature determines patterns of drug sensitivity and enrichment in immune target expression following EMT. European Journal of Cancer, 2014, 50, 143.	1.3	0
581	About CD45â˜/CD31+/CD105+ Circulating Cells in Patients with Gynecologic Malignanciesâ€”Letter. Clinical Cancer Research, 2014, 20, 1393-1393.	3.2	0
582	RAD50 Expression Predicts for Locoregional Failure and Distant Metastatic Recurrence After Postoperative Radiation Therapy in Resected Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S77-S78.	0.4	0
583	Nadir White Blood Cell, Absolute Neutrophil, and Absolute Lymphocyte Counts During Concurrent Chemoradiation Therapy Are Associated With Worse Outcomes in Patients With Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S623.	0.4	0
584	Influence of Surveillance PET/CT on Detection of Early Recurrence Following Chemoradiation in Stage III Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S664.	0.4	0
585	Predictors of Brain Metastasis After Prophylactic Cranial Irradiation for Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, S622-S623.	0.4	0
586	A Prospective Analysis of Factors Affecting Successful Clinical Trial Enrollment and Randomization in the Context of a Randomized Study of Aggressive Local Therapy in Oligometastatic Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, E362-E363.	0.4	0
587	Bevacizumab beyond disease progression for advanced nonâ€“small cell lung cancer: Does persistence have its rewards?. Cancer, 2016, 122, 1047-1049.	2.0	0
588	A high-throughput drug screen identifies new therapeutic vulnerabilities in non-small cell lung cancers (NSCLC) with overexpression of the EMT-associated receptor tyrosine kinase AXL. European Journal of Cancer, 2016, 69, S82.	1.3	0
589	Impact of co-mutations on the immune microenvironment of KRAS-mutant lung adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, S13-S14.	0.5	0
590	Consolidative local therapy in oligometastatic patients â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e62.	5.1	0
591	P2.01-054 Lung Cancer PD-L1 mRNA Expression Profile and Clinical Outcomes - An Analysis From The Cancer Genome Atlas and Cancer Cell Line Encyclopedia. Journal of Thoracic Oncology, 2017, 12, S818-S819.	0.5	0
592	P2.01-061 Image Analysis-Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non-Small Cell Lung Carcinomas. Journal of Thoracic Oncology, 2017, 12, S823-S824.	0.5	0
593	P2.02-014 Perioperative Outcomes and Downstaging Following Neoadjuvant Therapy For Lung Cancer â€“ Analysis of the National Cancer Database. Journal of Thoracic Oncology, 2017, 12, S854-S855.	0.5	0
594	P2.03b-023 Circulating Tumor DNA (ctDNA)-Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC). Journal of Thoracic Oncology, 2017, 12, S947-S948.	0.5	0

#	Article	IF	Citations
595	P2.05-015 Long-Term Outcomes of Prospective Phase ĐŸ Clinical Trial for Stereotactic Ablation Radiotherapy in Recurrent NSCLC. Journal of Thoracic Oncology, 2017, 12, S1039-S1040.	0.5	0
596	OA19.02 Sex Differences Are Detected in the Profile of Tumor Associated Inflammatory Cells (TAICs) Are Lung Adenocarcinoma. Journal of Thoracic Oncology, 2017, 12, S318.	0.5	0
597	OA20.05 The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non-Small Cell Lung Carcinomas. Journal of Thoracic Oncology, 2017, 12, S323-S324.	0.5	0
598	Diffusion Capacity of the Lungs Following Passive-Scattering Proton Therapy and Intensity-Modulated Photon Radiation Therapy for Locally Advanced Nonâ€“small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, E453-E454.	0.4	0
599	7-year Follow-Up Outcomes After Stereotactic Ablation Radiation Therapy for Stage I NSCLC: Results of a Phase 2 Clinical Trial. International Journal of Radiation Oncology Biology Physics, 2017, 99, E498.	0.4	0
600	Radiation Followed By an Anti-OX40 Immune Therapy Inhibits Anti-PD1-Resistant Tumors and Promotes Abscopal Effects. International Journal of Radiation Oncology Biology Physics, 2017, 99, S128.	0.4	0
601	RAD50 Expression Is Associated with Poor Clinical Outcomes after Radiotherapy in Resected Nonâ€“Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, S200.	0.4	0
602	Quantitative Proteomic Analysis of Core-Needle Biopsy of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, S1540-S1541.	0.5	0
603	CMET-09. PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS. Neuro-Oncology, 2017, 19, vi40-vi41.	0.6	0
604	OA 13.01 CD38-Mediated Immunometabolic Suppression as a Mechanism of Resistance to PD-1/PD-L1 Axis Blockade. Journal of Thoracic Oncology, 2017, 12, S1779.	0.5	0
605	P3.02-076 Glutaminase Inhibitor CB-839 Radiosensitizes KRAS-Mutant Lung Cancer Cells in a LKB1- and KEAP1/NRF2-Pathway Dependent Manner. Journal of Thoracic Oncology, 2017, 12, S2265.	0.5	0
606	P3.03-027 LKB1 Loss Is Associated with Resistance to Anti-Angiogenic Therapy in Non-Small Cell Lung Cancer Mouse Models. Journal of Thoracic Oncology, 2017, 12, S2283.	0.5	0
607	OA 07.02 Characteristics of Lung Cancer Cell-Free Tumor DNA (CfDNA) Shedding and Correlation with Tumor Burden as Measured by RECIST. Journal of Thoracic Oncology, 2017, 12, S1761.	0.5	0
608	OA 09.05 Identification of Novel Potentially Targetable Genomic Alterations in Paired Tumors with Acquired EGFR TKI Resistance by NGS. Journal of Thoracic Oncology, 2017, 12, S1768-S1769.	0.5	0
609	LKB1 loss is a novel genomic predictor of de novo resistance to PD-1/PD-L1 axis blockade in KRAS-mutant lung adenocarcinoma. Annals of Oncology, 2017, 28, v467.	0.6	0
610	Reply to Lambros et al. Modern Pathology, 2018, 31, 541-542.	2.9	0
611	P3.03-28 LKB1 Mutation Status is Associated with Poor Radiation Outcome in Patients with Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S921.	0.5	0
612	Phase I Trial of MK-3475 and Concurrent Radiation for the Elimination of Extensive-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, S18.	0.4	0

#	Article	IF	Citations
613	DNA damaging agents and immunotherapy in NSCLC: Is there a STING in the tale?. Annals of Oncology, 2018, 29, viii45.	0.6	0
614	Predictive Model of Progression in Early Stage Non Small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 102, e672-e673.	0.4	0
615	P1.03-12 PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers. Journal of Thoracic Oncology, 2018, 13, S516.	0.5	0
616	P2.01-87 Profiling the Symptom Burden of Patients with Metastatic NSCLC Receiving Either Chemotherapy or Targeted Therapy: Real-World Data. Journal of Thoracic Oncology, 2018, 13, S698.	0.5	0
617	P3.15-29 Defining the Symptom Burden of Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S1001-S1002.	0.5	0
618	P3.09-27 Histopathologic Parameters Define Features of Treatment Response to Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, S958.	0.5	0
619	P2.04-25 Randomized Clinical Trial Comparing Immunotherapy Plus SABR (I-SABR) Versus SABR Alone for Early Stage NSCLC. Journal of Thoracic Oncology, 2018, 13, S740.	0.5	0
620	Phase I Trial of MK-3475 and Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 102, e727.	0.4	0
621	Prognostic factors in RET dependent cancers treateded with RET inhibitors in early phase clinical trials.. Journal of Clinical Oncology, 2021, 39, 3117-3117.	0.8	0
622	Tumor Angiogenesis: General Principles and Therapeutic Approaches. , 2005, , 41-55.		0
623	Abstract 5556: Identification of signaling pathways active in small cell lung cancer (SCLC) compared to non-small cell lung cancer (NSCLC) by proteomic profiling. , 2010, , .		0
624	Abstract 306: KRas mediated induction of HIF-1Î± in normoxia promotes tumorigenesis and identifies HIF-1Î± as a therapeutic target. , 2010, , .		0
625	Abstract 4648: High membrane carbonic anhydrase IX (CAIX) expression predicts relapse of resected stage I-II non-small cell lung cancer (NSCLC). , 2010, , .		0
626	Abstract 1981: MYC downregulation and chemoresistance in non-small cell lung cancer (NSCLC): Evidence from the Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) program. , 2010, , .		0
627	Use of cytokines to predict on-target toxicity in patients with recurrent glioblastoma treated with aflibercept.. Journal of Clinical Oncology, 2010, 28, e12507-e12507.	0.8	0
628	Abstract 4031: CNG c-myc in mesothelioma. , 2011, , .		0
629	Abstract 3269: VEGF inhibitor resistance is associated with stromal EGFR activation and normalized revascularization in an orthotopic model of lung adenocarcinoma. , 2011, , .		0
630	Abstract 955: Specific forms of mutantKRASpredict patient benefit from targeted therapy in the BATTLE-1 clinical trial in advanced non-small cell lung cancer. , 2011, , .		0

#	Article	IF	Citations
631	Abstract 4109: A 5-gene signature (sig) predicts clinical benefit from erlotinib in non-small cell lung cancer (NSCLC) patients (pts) harboring wild-type (wt) EGFR & KRAS. , 2011, , .		0
632	Abstract 392: CXCR2 expression in tumor cells is associated with an adverse outcome in a large set of non-small-cell lung cancer (NSCLC). , 2011, , .		0
633	Abstract 3196: EZH2 expression is an early event in the pathogenesis of non-small cell lung cancer (NSCLC) and correlates with tumor progression. , 2011, , .		0
634	Use of a gene expression signature related to epithelial-to-mesenchymal transition (EMT) to predict for overall survival (OS) in cohorts of lung and head and neck cancer (HNSCC) patients.. Journal of Clinical Oncology, 2011, 29, 7010-7010.	0.8	0
635	Prognostic effects of circulating markers of epithelial mesenchymal transition (EMT) in metastatic colorectal cancer patients.. Journal of Clinical Oncology, 2012, 30, 456-456.	0.8	0
636	Abstract IA3: Lung cancer stem cells, acquired vulnerabilities, and molecular portraits: Translation to the clinic. Clinical Cancer Research, 2012, 18, IA3-IA3.	3.2	0
637	Abstract A12: High-throughput mutation analysis of NSCLC circulating tumor cells. Clinical Cancer Research, 2012, 18, A12-A12.	3.2	0
638	Abstract 1099: MiR-200c overexpression radiosensitizes lung cancer cells. , 2012, , .		0
639	Abstract 207: Casitas B-lineage lymphoma-3 is an epigenetically regulated gene whose knockdown induces mesenchymal to epithelial transition and enhances erlotinib sensitivity in lung cancer cell lines. , 2012, , .		0
640	Abstract LB-347: Identify signaling responses to MEK inhibitor AZD6244 in lung cancer cells with proteomics reverse phase protein array. , 2012, , .		0
641	Abstract 3454: Establishing role of KRAS mutation on NSCLC radio-sensitivity. , 2012, , .		0
642	Abstract 5605:LKB1andKRASmutations predict resistance to PI3K/Akt inhibitors in non-small cell lung cancer. , 2012, , .		0
643	Abstract 4645: Plasma cytokine and angiogenic factor (CAF) profiling for identification of markers associated with clinical benefit from bevacizumab (BEV) and with primary tumor presence in a phase II presurgical study of metastatic renal cell carcinoma (mRCC) patients. , 2013, , .		0
644	Abstract 4442: Enhancement of radiation response in KRAS mutant non-small cell lung cancer cells with the MEK inhibitor GSK1120212.. , 2013, , .		0
645	Abstract 5589: Molecular signatures of in vitro drug response in lung cancer.. , 2013, , .		0
646	Abstract 4421: Onco Vasculomics(tm): A 3-d tumor vasculature assessment methodology for quantifying mechanism and efficacy of discovery-stage anti-cancer compounds.. , 2013, , .		0
647	Abstract B08: High-throughput synthetic lethal drug screen to identify novel radiation sensitizers for KRAS mutant non-small cell lung cancer. , 2013, , .		0
648	Abstract A1: Onco Vasculomics (TM): A 3D tumor micro-vascular environment assessment methodology for quantifying mechanism of efficacy and toxicity of discovery-stage anti-cancer compounds.. , 2013, , .		0

#	Article	IF	Citations
649	Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma.. , 2013, , .		0
650	Il-8 as an underutilized prognostic factor in metastatic colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 409-409.	0.8	0
651	Abstract A21: microRNA-200 regulates tumor cell PD-L1 expression to control lung cancer metastasis.. Clinical Cancer Research, 2014, 20, A21-A21.	3.2	0
652	Intratumor heterogeneity (ITH) of lung adenocarcinomas defined by multiregion whole exome sequencing (WES).. Journal of Clinical Oncology, 2014, 32, 11032-11032.	0.8	0
653	Abstract 3702: Integrated genomic and proteomic analysis identifies PTEN loss and AKT/MTOR as drivers of resistance to MEK inhibitors in NSCLC cells. , 2014, , .		0
654	Abstract 5220: Reciprocal regulation of MYC and LKB1 modulates cell survival and differentiation in lung cancer. , 2014, , .		0
655	Abstract 5480: NSCLC cells with LKB1 mutation are vulnerable to energetic and oxidative stresses induced by 8-Chloroadenosine. , 2014, , .		0
656	Abstract 903: Evaluation of predictive biomarkers and resistance mechanisms of PI3K pathway inhibition in head and neck squamous cell carcinoma. , 2014, , .		0
657	Abstract 29: Myeloid cell and plasma cytokine and angiogenic factor (CAF) dynamics in association with response to VEGFR inhibitors cediranib and sunitinib. , 2014, , .		0
658	Abstract 4898: High content clonogenic survival assay for drug library screening identifies potent radiation sensitizers for non-small cell lung cancer. , 2014, , .		0
659	Abstract 1040: An integrated analysis of EMT across diverse cancer types identifies new potential therapeutic targets. , 2014, , .		0
660	Abstract 3559: Long non-coding RNA subtype classification of clear-cell renal cell carcinoma. , 2014, , .		0
661	Abstract 1541: Co-mutations define major subsets ofKRAS-driven lung adenocarcinoma with implications for targeted cancer therapy. , 2014, , .		0
662	Genomic heterogeneity of lung cancers and its potential clinical implications.. Journal of Clinical Oncology, 2015, 33, 7530-7530.	0.8	0
663	Association of epithelial-mesenchymal transition with an immunosuppressive, inflammatory tumor microenvironment with elevated levels of checkpoint inhibitors in lung adenocarcinoma.. Journal of Clinical Oncology, 2015, 33, 3030-3030.	0.8	0
664	Abstract 968: Co-occurring genomic alterations define major subsets ofKRAS-mutant lung adenocarcinoma (LUAC) with distinct biology and therapeutic vulnerabilities. , 2015, , .		0
665	Abstract 3441: Proteomic profiling identifies PTK2/FAK as a targetable marker of radioresistance in head and neck cancer. , 2015, , .		0
666	Abstract 673: Vulnerability of LKB1 deficient NSCLC to C8-modified adenosine analogs is associated with diminished autophagy induction. , 2015, , .		0

#	Article	IF	Citations
667	Abstract 2150: Impact of co-occurring genetic events on RAS signaling diversification inNF1-mutant lung adenocarcinoma (LUAC). , 2015, , .		0
668	Abstract 3364: Epithelial-mesenchymal transition is associated with a profound inflammatory tumor microenvironment in lung adenocarcinoma. , 2015, , .		0
669	Abstract 3623: Neoadjuvant chemotherapy is associated with increased expression of DNA repair proteins and epithelial to mesenchymal transition (EMT) in patients with non-small cell lung cancer (NSCLC). , 2015, , .		0
670	Abstract 3579: Identification of biomarkers of AXL-mediated drug resistance in head and neck squamous cell carcinoma. , 2015, , .		0
671	Abstract 456: Defined co-mutation subgroups of KRAS-mutated NSCLC display distinct immune profiles. , 2015, , .		0
672	Abstract 3900: Genomic landscape of human cancer reveals dysregulated TGF-Î² signaling with prognostic significance. , 2015, , .		0
673	Abstract 2982: Genome sequencing reveals the multicentric nature of multiple synchronous lung adenocarcinomas. , 2015, , .		0
674	Abstract 2118: Nonsense-mediated decay regulates the expression of tumor suppressor transcripts and cancer pathways in non-small cell lung cancer cell lines. , 2015, , .		0
675	Abstract LB-222: Long-term subclonal evolution of CLL from immune selective pressure after allogeneic stem cell transplant and donor lymphocyte infusion. , 2015, , .		0
676	Abstract B67: A big role in tumor immune microenvironment of a small non-coding RNA: microRNA-200. , 2015, , .		0
677	Abstract A05: Targeting the EMT-immunosuppression loop in lung cancer as a strategy to prevent metastasis. , 2016, , .		0
678	Abstract PR01: Targeting the EMT-immunosuppression loop in lung cancer as a strategy to prevent metastasis. , 2016, , .		0
679	Clinical utilization of a CLIA-certified cell-free DNA (cfDNA) blood test for identification of targetable molecular alterations in patients with non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e23064-e23064.	0.8	0
680	Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.. Journal of Clinical Oncology, 2016, 34, 2546-2546.	0.8	0
681	Preliminary analysis of genomic profiling of small cell lung cancer in Chinese population revealed frequent PIK3CA hotspot mutations.. Journal of Clinical Oncology, 2016, 34, e20089-e20089.	0.8	0
682	Proteomic and mRNA expression analysis identifies PDL-1 expression as a marker of treatment failure in head and neck cancer.. Journal of Clinical Oncology, 2016, 34, 6042-6042.	0.8	0
683	The CDK4/6 inhibitor G1T28 to protect immune cells and fibroblasts from chemotherapy and radiation-induced toxicity in vitro and to maintain efficacy of chemotherapy in SCLC Rb-deficient cells.. Journal of Clinical Oncology, 2016, 34, e20099-e20099.	0.8	0
684	Reprogramming of cell signaling in response to MEK inhibition in non-small cell cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, e23222-e23222.	0.8	0

#	Article	IF	Citations
685	Abstract 4137: Loss of LKB1 mediates an immune inert phenotype in human lung adenocarcinoma. , 2016, , .		0
686	Abstract LB-170: Unique microRNA signatures in small cell lung cancer correlate with distinct protein expression profiles and drug response. , 2016, , .		0
687	Abstract 3272: LKB1 loss is associated with resistance to VEGF inhibitors in non-small cell lung cancer (NSCLC). , 2016, , .		0
688	Abstract 156: Integrated exome and transcriptome sequencing of primary lung cancers and paired distant metastases. , 2016, , .		0
689	Abstract 4662: Beta blockers abrogate EGFR TKI resistance induced by adrenergic receptor-mediated upregulation of IL-6 and modulation of the LKB1/AMPK/mTOR axis. , 2016, , .		0
690	Abstract 4799: Inhibition of HER2 mutant non-small cell lung cancer using 3rd generation EGFR/HER2 inhibitors. , 2016, , .		0
691	Abstract CT075: Tumor mutation status will predict metabolic response to metformin in lung cancer treated with stereotactic body radiation therapy (SBRT). , 2016, , .		0
692	Abstract 4665: The combination of polo-like kinase 1 inhibition and erlotinib overcomes T790M-mediated drug resistancein vitroandin vivoin non-small cell lung cancer. , 2016, , .		0
693	Abstract 809: Dietary iron intake, genetic variants in microRNA related iron regulatory pathway genes, and the risk of non-small cell lung cancer. , 2016, , .		0
694	Abstract 532: Impact of APOBEC mutagenesis on the immune microenvironment of lung adenocarcinoma (LUAC). , 2016, , .		0
695	Abstract 1749: Different dietary patterns and reduction of lung cancer risk: a large case-control study in the U.S. Cancer Research, 2016, 76, 1749-1749.	0.4	0
696	Abstract A086: EMT produces an immunosuppressive tumor microenvironment. , 2016, , .		0
697	Comprehensive molecular and immune profiling of non-small cell lung cancer and matched distant metastases to suggest distinct molecular mechanisms underlying metastasis.. Journal of Clinical Oncology, 2017, 35, 8541-8541.	0.8	0
698	Multiregion gene-expression profiling to reveal heterogeneity in molecular subtypes and immunotherapy response signatures in lung cancer.. Journal of Clinical Oncology, 2017, 35, e20077-e20077.	0.8	0
699	Genomic and transcriptomic profiling of localized sarcomatoid carcinoma of the lung to reveal association between immune activation and a lower risk of recurrence.. Journal of Clinical Oncology, 2017, 35, e20058-e20058.	0.8	0
700	Interplay between immune infiltration and tumor progression and survival in non-small cell lung cancer: An analysis of institutional and public data.. Journal of Clinical Oncology, 2017, 35, 8538-8538.	0.8	0
701	Local consolidation therapy (LCT) after first line tyrosine kinase inhibitor (TKI) for patients with EGFR mutant metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2017, 35, e20654-e20654.	0.8	0
702	Simultaneous molecular alterations in solid tumors with IDH1 or IDH2 mutations.. Journal of Clinical Oncology, 2017, 35, 11609-11609.	0.8	0

#	Article	IF	Citations
703	TCR repertoire sequencing of 254 resected non-small cell lung cancers to reveal TCR clonality in normal tissues compared to tumor tissues.. Journal of Clinical Oncology, 2017, 35, 11500-11500.	0.8	0
704	Abstract 4745: Circulating cytokine levels predictive of Gradeâ‰¥3 radiation pneumonitis: Preliminary secondary analysis of a randomized controlled trial of definitive chemoradiation in locally advanced NSCLC. , 2017, , .		0
705	Abstract 298: WEE1 inhibitor activity correlates to AXL/mTOR expression and exhibits synergy with temozolomide (TMZ) in small cell lung cancer (SCLC). , 2017, , .		0
706	Abstract 567: CD38 blockade overcomes the immune resistance to anti-PD-L1 therapy by boosting CD8 T cell response. , 2017, , .		0
707	Abstract 627:NLRC5co-mutations are associated with impaired antigen presentation and immune exclusion inKRAS-mutant lung adenocarcinoma. , 2017, , .		0
708	Abstract 2934: Neoadjuvant chemotherapy influence changes of the immune response in non-small cell lung carcinomas immune response in non-small cell lung carcinomas. , 2017, , .		0
709	Abstract 1560: Differential sensitivity analysis for resistant malignancies (DISARM), a novel approach for drug screen analysis, identifies common candidate drugs across platinum-resistant cancer types. , 2017, , .		0
710	Abstract 2774: Correlative analysis of systemic markers from a randomized trial assessing local consolidative therapy for non-small cell lung cancer (NSCLC) patients with oligometastatic disease. , 2017, , .		0
711	Abstract 1960: T790M-independent EGFR TKI resistance is associated with a broad multi-drug resistant phenotype but selective vulnerabilities to spindle assembly complex (SAC) and CDK inhibitors. , 2018, , .		0
712	Abstract 1268: Anti-PD-1 monotherapy outperforms multiple immunotherapy combination strategies in an oral cancer prevention mouse model. , 2018, , .		0
713	Abstract 2822: ATR inhibitors are active as single agents and in combination with PARP1 and ATM inhibitors in molecularly distinct subsets of small cell lung cancer models. , 2018, , .		0
714	Abstract 990: Single-cell profiling of small cell lung cancer circulating tumor cell-derived xenograft models reveals intratumoral heterogeneity among mediators of chemoresistance. , 2018, , .		0
715	Abstract 3633: Immunofluorescence profiling of co-expression of multiple immune checkpoints in malignant and tumor infiltrated lymphocytes in non-small cell lung carcinomas using image analysis system. , 2018, , .		0
716	Abstract 5147: Lactate transporters are a potential therapeutic target for LKB1-deficient lung cancers. , 2018, , .		0
717	Abstract 2956: Mechanisms of resistance for osimertinib for patients withEGFR-mutant lung cancer: MD Anderson Cancer Center single institution experience with osimertinib resistance. , 2018, , .		0
718	Abstract 1838: A pre-existing rare PIK3CAE545Ksubpopulation confers clinical resistance to MEK plus CDK4/6 inhibition in NRAS melanoma and is dependent on S6K1 signaling. , 2018, , .		0
719	Tracking circulating cell-free tumor DNA in gastric cancer to detect early disease recurrence.. Journal of Clinical Oncology, 2019, 37, e14571-e14571.	0.8	0
720	Distinct resistant mechanism and genomic evolution during TKI treatment in non-small cell lung cancer patients with or without acquired T790M mutation.. Journal of Clinical Oncology, 2019, 37, e20603-e20603.	0.8	0

#	Article	IF	Citations
721	Pathogenic germline mutation profile in Chinese lung cancers and related-driver mutation pattern.. Journal of Clinical Oncology, 2019, 37, e13003-e13003.	0.8	0
722	cfDNA analysis to reveal association of genomic features with chemotherapy response and survival in patients with pulmonary large-cell neuroendocrine carcinoma.. Journal of Clinical Oncology, 2019, 37, e14555-e14555.	0.8	0
723	Abstract 5028: Characterization of the tumor immune microenvironment in treatment-naÃ¯ve EGFR-mutant NSCLC uncovers a low IFN-gamma suppressive immune phenotype. , 2019, , .		0
724	Abstract 347: Identification of poziotinib alone or in combination with TDM1 as a pan-HER2 inhibitor. , 2019, , .		0
725	Abstract 276: Targeting AXL sensitizes non-small cell lung cancer to ATR inhibitors by enhancing replication stress. , 2019, , .		0
726	Abstract 1176: Immunogenomic profiling identifies a subgroup of squamous cell lung cancers with immunosuppressed tumor microenvironment and correlates TGF-beta and Wnt/beta-catenin signaling as predictive of low PD-L1 expression. , 2019, , .		0
727	Outcomes to first-line pembrolizumab in patients with PD-L1-high (â‰¥50%) non-small-cell lung cancer and a poor performance status.. Journal of Clinical Oncology, 2020, 38, 9568-9568.	0.8	0
728	In Response. Journal of Thoracic Oncology, 2022, 17, e39.	0.5	0
729	Abstract 3507: LKB1 deficiency and KEAP1/NRF2 pathway alterations as biomarkers of response for ATR and ATM inhibitors and other inhibitors of DNA damage response (DDR) in NSCLC. , 2019, , .		0
730	Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC.. Journal of Clinical Oncology, 2022, 40, 9061-9061.	0.8	0
731	Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic nonâ€“small cell lung cancer.. Journal of Clinical Oncology, 2022, 40, 9055-9055.	0.8	0
732	Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.. Journal of Clinical Oncology, 2022, 40, e21169-e21169.	0.8	0
733	Molecular parameters impacting the success rate of a lung cancer PDX model.. Journal of Clinical Oncology, 2022, 40, e20592-e20592.	0.8	0